

# Paul M Ridker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7779003/publications.pdf>

Version: 2024-02-01

954  
papers

222,007  
citations

9

214  
h-index

25

440  
g-index

988  
all docs

988  
docs citations

988  
times ranked

124625  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovascular Research, 2022, 118, 897-903.	3.8	17
2	Genetic overlap analysis of endometriosis and asthma identifies shared loci implicating sex hormones and thyroid signalling pathways. Human Reproduction, 2022, 37, 366-383.	0.9	19
3	Proteomics for the prediction and prevention of atherosclerotic disease. European Heart Journal, 2022, 43, 1578-1581.	2.2	3
4	Dissecting the IL6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. British Journal of Clinical Pharmacology, 2022, 88, 2875-2884.	2.4	29
5	Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles. Clinical Pharmacology and Therapeutics, 2022, 111, 950-955.	4.7	7
6	Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nature Genetics, 2022, 54, 152-160.	21.4	135
7	Clinical predictors of COVID-19 severity and bleeding in the ACTIV4B COVID-19 outpatient thrombosis prevention trial. American Journal of Hematology, 2022, 97, .	4.1	4
8	Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1. Scientific Reports, 2022, 12, 4266.	3.3	0
9	Thromboinflammation and Antithrombotics in COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1234.	7.4	9
10	IL6-Driven Clonal Hematopoiesis and Response to Canakinumab. JAMA Cardiology, 2022, 7, 521.	6.1	125
11	ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. Current Atherosclerosis Reports, 2022, 24, 585-597.	4.8	8
12	Targeting cardiovascular inflammation: next steps in clinical translation. European Heart Journal, 2021, 42, 113-131.	2.2	186
13	COVID-19 – A vascular disease. Trends in Cardiovascular Medicine, 2021, 31, 1-5.	4.9	254
14	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. American Heart Journal, 2021, 231, 121-127.	2.7	60
15	The neutrophil-lymphocyte ratio: considerations for clinical application. European Heart Journal, 2021, 42, 2216-2217.	2.2	9
16	Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates. Journal of the American College of Cardiology, 2021, 77, 1856-1858.	2.8	19
17	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiology, 2021, 6, 437.	6.1	82
18	Association Between Hemostatic Profile and Migraine. Neurology, 2021, 96, e2481-e2487.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial. ACR Open Rheumatology, 2021, 3, 371-380.	2.1	8
20	Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circulation Research, 2021, 128, 1728-1746.	4.5	238
21	IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, The, 2021, 397, 2060-2069.	13.7	268
22	The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021, 53, 840-860.	21.4	341
23	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal, 2021, 42, 2439-2454.	2.2	491
24	Homocysteine Is Associated With Future Venous Thromboembolism in 2 Prospective Cohorts of Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2215-2224.	2.4	15
25	Targeting cytokine storm in COVID-19: what have we learned?. European Heart Journal Open, 2021, 1, .	2.3	3
26	Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study. Journal of Cardiovascular Computed Tomography, 2021, 15, 372-379.	1.3	17
27	Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein) Tj ETQq1 <sub>3.6</sub> 1.0.784314 rgBT /Ov e003288.	1.3	17
28	Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. Circulation Genomic and Precision Medicine, 2021, 14, e003330.	3.6	19
29	Association Between Achieved ̳-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk. JAMA Cardiology, 2021, 6, 910.	6.1	52
30	From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?. Cardiovascular Research, 2021, 117, e138-e140.	3.8	39
31	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	27.8	183
32	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	3.1	11
33	Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 3197-3207.	6.1	11
34	Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy. Journal of the American College of Cardiology, 2021, 78, 1114-1123.	2.8	9
35	Lipoproteins in chronic kidney disease: from bench to bedside. European Heart Journal, 2021, 42, 2170-2185.	2.2	32
36	The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. European Heart Journal, 2021, 42, 896-903.	2.2	152

#	ARTICLE	IF	CITATIONS
37	Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. <i>Neurology</i> , 2021, 97, e2223-e2235.	1.1	7
38	Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial. <i>Circulation Genomic and Precision Medicine</i> , 2021, , CIRCGEN121003440.	3.6	0
39	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1703.	7.4	186
40	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. <i>Rheumatology</i> , 2021, 60, 2963-2968.	1.9	3
41	The power of genetic diversity in genome-wide association studies of lipids. <i>Nature</i> , 2021, 600, 675-679.	27.8	353
42	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and high-sensitivity C-reactive protein in <scp>CANTOS</scp>. <i>Arthritis Care and Research</i> , 2021, , .	3.4	3
43	Additive and Multiplicative Interactions Between Genetic Risk Score and Family History and Lifestyle in Relation to Risk of Type 2 Diabetes. <i>American Journal of Epidemiology</i> , 2020, 189, 445-460.	3.4	17
44	Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 31-40.	5.6	136
45	Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1 $\beta$ inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. <i>European Heart Journal</i> , 2020, 41, 2153-2163.	2.2	148
46	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , 2020, 11, 163.	12.8	466
47	Hypothyroidism and Kidney Function: A Mendelian Randomization Study. <i>Thyroid</i> , 2020, 30, 365-379.	4.5	27
48	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Riskâ€”A Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 199-206.	3.4	5
49	Effects of Interleukin-1 $\beta$ Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk. <i>Hypertension</i> , 2020, 75, 477-482.	2.7	69
50	Inhibition of IL1 $\beta$ by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. <i>Cancer Research</i> , 2020, 80, 5597-5605.	0.9	58
51	Targeting Interleukin-1 and Interleukin-6. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1774-1776.	2.8	12
52	Coronavirus 2019 Disease (COVIDâ€19), Systemic Inflammation, and Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e017756.	3.7	41
53	Adverse Effects of Lowâ€Dose Methotrexate in a Randomized Doubleâ€Blind Placeboâ€Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 697-704.	2.1	18
54	Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. <i>Nature Genetics</i> , 2020, 52, 1314-1332.	21.4	91

#	ARTICLE	IF	CITATIONS
55	Effects of Interleukin-1 $\beta$ Inhibition on Incident Anemia. <i>Annals of Internal Medicine</i> , 2020, 172, 523.	3.9	37
56	Effects of Interleukin-1 $\beta$ Inhibition on Incident Hip and Knee Replacement. <i>Annals of Internal Medicine</i> , 2020, 173, 509-515.	3.9	84
57	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2020, 2, 400-410.	4.0	8
58	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 172, 369.	3.9	126
59	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2268.	7.4	540
60	Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 2065-2071.	5.6	26
61	Inhibition of Interleukin-1 $\beta$ and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1660-1670.	2.8	110
62	Genetic Studies of Leptin Concentrations Implicate Leptin in the Regulation of Early Adiposity. <i>Diabetes</i> , 2020, 69, 2806-2818.	0.6	26
63	Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016507.	3.7	21
64	Equipoise, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID. <i>Circulation</i> , 2020, 142, 2296-2298.	1.6	2
65	Habitual sleep disturbances and migraine: a Mendelian randomization study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2370-2380.	3.7	18
66	Gene-educational attainment interactions in a multi-ancestry genome-wide meta-analysis identify novel blood pressure loci. <i>Molecular Psychiatry</i> , 2020, 26, 2111-2125.	7.9	17
67	Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood. <i>European Journal of Epidemiology</i> , 2020, 35, 685-697.	5.7	9
68	Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose. <i>PLoS ONE</i> , 2020, 15, e0230815.	2.5	10
69	Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002872.	3.6	90
70	Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2281.	7.4	81
71	Role of Rare and Low-Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002772.	3.6	11
72	From CANTOS to CIRT to COLCOT to Clinic. <i>Circulation</i> , 2020, 141, 787-789.	1.6	77

#	ARTICLE	IF	CITATIONS
73	Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. <i>European Heart Journal</i> , 2020, 41, 2952-2961.	2.2	72
74	Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2122-2135.	2.8	160
75	The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. <i>Atherosclerosis</i> , 2020, 301, 37-43.	0.8	24
76	Association of Genetic Variants With Migraine Subclassified by Clinical Symptoms in Adult Females. <i>Frontiers in Neurology</i> , 2020, 11, 617472.	2.4	5
77	Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study. <i>JAMA Network Open</i> , 2020, 3, e2025466.	5.9	28
78	Genetic loci associated with prevalent and incident myocardial infarction and coronary heart disease in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. <i>PLoS ONE</i> , 2020, 15, e0230035.	2.5	5
79	Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose. , 2020, 15, e0230815.		0
80	Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose. , 2020, 15, e0230815.		0
81	Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose. , 2020, 15, e0230815.		0
82	Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose. , 2020, 15, e0230815.		0
83	Genome-wide meta-analysis of macronutrient intake of 91,114 European ancestry participants from the cohorts for heart and aging research in genomic epidemiology consortium. <i>Molecular Psychiatry</i> , 2019, 24, 1920-1932.	7.9	44
84	Integrating children's physical activity enjoyment into public health dialogue (United States). <i>Health Promotion International</i> , 2019, 34, 144-153.	1.8	10
85	Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. <i>Blood</i> , 2019, 134, 1645-1657.	1.4	162
86	Plasma Placental Growth Factor Concentrations Are Elevated Well in Advance of Type 2 Diabetes Mellitus Onset: Prospective Data From the WHS. <i>Journal of the American Heart Association</i> , 2019, 8, e012790.	3.7	4
87	Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. <i>Nature Medicine</i> , 2019, 25, 1761-1771.	30.7	157
88	Associations of autozygosity with a broad range of human phenotypes. <i>Nature Communications</i> , 2019, 10, 4957.	12.8	84
89	Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. <i>Nature Communications</i> , 2019, 10, 4857.	12.8	90
90	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. <i>European Heart Journal</i> , 2019, 40, 3901-3909.	2.2	54

#	ARTICLE	IF	CITATIONS
91	World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. <i>The Lancet Global Health</i> , 2019, 7, e1332-e1345.	6.3	554
92	Association of Birth Weight With Type 2 Diabetes and Glycemic Traits. <i>JAMA Network Open</i> , 2019, 2, e1910915.	5.9	41
93	Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies. <i>BioDrugs</i> , 2019, 33, 571-579.	4.6	9
94	A large-scale exome array analysis of venous thromboembolism. <i>Genetic Epidemiology</i> , 2019, 43, 449-457.	1.3	22
95	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. <i>American Journal of Epidemiology</i> , 2019, 188, 1033-1054.	3.4	85
96	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	13.7	512
97	Anticytokine Agents. <i>Circulation Research</i> , 2019, 124, 437-450.	4.5	188
98	Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 144.	6.1	64
99	Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity. <i>Nature Communications</i> , 2019, 10, 376.	12.8	64
100	COMT Effects on Vitamin E and Colorectal Cancer, in-vitro and in Two Randomized Trials (P15-005-19). <i>Current Developments in Nutrition</i> , 2019, 3, nzz037.P15-005-19.	0.3	2
101	Genetic variation at the coronary artery disease risk locus <i>GUCY1A3</i> modifies cardiovascular disease prevention effects of aspirin. <i>European Heart Journal</i> , 2019, 40, 3385-3392.	2.2	25
102	Stress-Associated Neurobiological Pathway Linking Socioeconomic Disparities to Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3243-3255.	2.8	109
103	Genome-wide analysis of dental caries and periodontitis combining clinical and self-reported data. <i>Nature Communications</i> , 2019, 10, 2773.	12.8	183
104	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
105	Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. <i>American Journal of Human Genetics</i> , 2019, 105, 15-28.	6.2	21
106	Dairy Intake and Body Composition and Cardiometabolic Traits among Adults: Mendelian Randomization Analysis of 182041 Individuals from 18 Studies. <i>Clinical Chemistry</i> , 2019, 65, 751-760.	3.2	20
107	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019, 51, 957-972.	21.4	549
108	Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2723-2725.	3.6	4



#	ARTICLE	IF	CITATIONS
109	Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease. PLoS ONE, 2019, 14, e0216222.	2.5	17
110	Group IIA Secretory Phospholipase A <sub>2</sub> , Vascular Inflammation, and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1182-1190.	2.4	25
111	Human Papillomavirus Infection. Circulation Research, 2019, 124, 677-678.	4.5	0
112	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 16.	2.4	109
113	A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure. Human Molecular Genetics, 2019, 28, 2615-2633.	2.9	31
114	Lipid levels and the risk of hemorrhagic stroke among women. Neurology, 2019, 92, e2286-e2294.	1.1	82
115	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nature Genetics, 2019, 51, 636-648.	21.4	112
116	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. Nature Genetics, 2019, 51, 452-469.	21.4	89
117	Elevated interleukin-6 and interleukin-18 concentrations predict residual inflammatory risk both before and after interleukin-1beta inhibition with canakinumab. European Heart Journal, 2019, 40, .	2.2	16
118	Clinical and demographic predictors of attenuated LDL-C response to PCSK9 inhibition with bococizumab: Insights from the SPIRE trials. European Heart Journal, 2019, 40, .	2.2	0
119	Catechol-O-Methyltransferase and Cardiovascular Disease: MESA. Journal of the American Heart Association, 2019, 8, e014986.	3.7	7
120	Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clinical Infectious Diseases, 2019, 68, 1877-1886.	5.8	42
121	Associations of Mitochondrial and Nuclear Mitochondrial Variants and Genes with Seven Metabolic Traits. American Journal of Human Genetics, 2019, 104, 112-138.	6.2	106
122	Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. European Heart Journal, 2019, 40, 621-631.	2.2	97
123	Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. Nature Genetics, 2019, 51, 51-62.	21.4	328
124	Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials. Journal of Internal Medicine, 2019, 285, 503-509.	6.0	32
125	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.	27.0	886
126	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation, 2019, 139, 1289-1299.	1.6	384



#	ARTICLE	IF	CITATIONS
127	Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. <i>Journal of the American College of Cardiology</i> , 2019, 73, 58-66.	2.8	147
128	COMT and Alpha-Tocopherol Effects in Cancer Prevention: Gene-Supplement Interactions in Two Randomized Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2019, 111, 684-694.	6.3	24
129	Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women's Genome Health Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 97-106.	2.4	10
130	Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. <i>Nature Communications</i> , 2018, 9, 1613.	12.8	78
131	Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. <i>Journal of Clinical Lipidology</i> , 2018, 12, 958-965.	1.5	44
132	Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. <i>Nature Genetics</i> , 2018, 50, 559-571.	21.4	356
133	A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure. <i>American Journal of Human Genetics</i> , 2018, 102, 375-400.	6.2	123
134	Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER. <i>Circulation</i> , 2018, 137, 1763-1766.	1.6	25
135	Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. <i>Circulation</i> , 2018, 138, 141-149.	1.6	151
136	Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1027-1038.	1.5	10
137	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2392-2401.	2.8	236
138	Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. <i>American Journal of Epidemiology</i> , 2018, 187, 705-716.	3.4	40
139	Inflammation, venous thromboembolism, and what we can do about it. <i>European Heart Journal</i> , 2018, 39, 3615-3617.	2.2	6
140	Will Reducing Inflammation Reduce Vascular Event Rates?. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 317-319.	5.3	11
141	Prospective study of plasma homocysteine, its dietary determinants, and risk of age-related macular degeneration in men. <i>Ophthalmic Epidemiology</i> , 2018, 25, 79-88.	1.7	15
142	Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. <i>Clinical Chemistry</i> , 2018, 64, 231-241.	3.2	10
143	Homocysteine, B Vitamins, MTHFR Genotype, and Incident Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2018, 2, 508-510.	2.4	3
144	Dairy Consumption and Body Mass Index Among Adults: Mendelian Randomization Analysis of 184802 Individuals from 25 Studies. <i>Clinical Chemistry</i> , 2018, 64, 183-191.	3.2	34

#	ARTICLE	IF	CITATIONS
145	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 319-328.	13.7	628
146	Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2870-2878.	2.4	15
147	Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?. <i>European Heart Journal</i> , 2018, 39, 4109-4111.	2.2	44
148	IL-1 $\beta$ Inhibition Reduces Atherosclerotic Inflammation in HIV Infection. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2809-2811.	2.8	59
149	Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women. <i>Journal of the American Heart Association</i> , 2018, 7, e007514.	3.7	20
150	Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3320-3331.	2.8	120
151	Psoriasis and Atherosclerosis. <i>Circulation Research</i> , 2018, 123, 1183-1184.	4.5	12
152	Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. <i>JAMA Network Open</i> , 2018, 1, e185708.	5.9	65
153	The prediction of therapy-benefit for individual cardiovascular disease prevention. <i>Current Opinion in Lipidology</i> , 2018, 29, 436-444.	2.7	21
154	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet</i> , The, 2018, 392, 1311-1320.	13.7	355
155	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018, 206, 80-93.	2.7	276
156	Meta-analysis of LDL-C Lowering and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1493.	7.4	0
157	Inflammation, Immunity, and Infection in Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2071-2081.	2.8	389
158	Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?. <i>New England Journal of Medicine</i> , 2018, 379, 1572-1574.	27.0	75
159	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. <i>American Journal of Human Genetics</i> , 2018, 103, 691-706.	6.2	326
160	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. <i>Nature Genetics</i> , 2018, 50, 1412-1425.	21.4	924
161	Relationship of Interleukin-1 $\beta$ Blockade With Incident Gout and Serum Uric Acid Levels. <i>Annals of Internal Medicine</i> , 2018, 169, 535.	3.9	74
162	P619 Incident premature coronary heart disease in women: an analysis of 53 biomarkers from the Women's Health Study. <i>European Heart Journal</i> , 2018, 39, .	2.2	0

#	ARTICLE	IF	CITATIONS
163	Inhibition of Interleukin-1 <sup>2</sup> by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2405-2414.	2.8	186
164	Family History of MI, Smoking, and Risk of Periodontal Disease. <i>Journal of Dental Research</i> , 2018, 97, 1106-1113.	5.2	12
165	Interleukin-1 inhibition and ischaemic stroke: has the time for a major outcomes trial arrived?. <i>European Heart Journal</i> , 2018, 39, 3518-3520.	2.2	8
166	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. <i>JAMA Internal Medicine</i> , 2018, 178, 1231.	5.1	58
167	Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 62.	2.4	72
168	Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. <i>Journal of the American College of Cardiology</i> , 2018, 72, 287-296.	2.8	73
169	Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. <i>Circulation</i> , 2018, 138, 2330-2341.	1.6	98
170	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). <i>European Heart Journal</i> , 2018, 39, 3499-3507.	2.2	375
171	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , 2018, 41, 1281-1288.	1.8	151
172	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , 2018, 50, 1225-1233.	21.4	552
173	Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. <i>PLoS ONE</i> , 2018, 13, e0198166.	2.5	94
174	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. <i>Nature Genetics</i> , 2018, 50, 26-41.	21.4	286
175	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. <i>Nature Genetics</i> , 2018, 50, 524-537.	21.4	1,124
176	Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?. <i>European Heart Journal</i> , 2017, 38, ehv287.	2.2	17
177	Rare and low-frequency coding variants alter human adult height. <i>Nature</i> , 2017, 542, 186-190.	27.8	544
178	Sex Differences in Inflammatory Markers and Health Status Among Young Adults With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, e003470.	2.2	38
179	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. <i>Clinical Chemistry</i> , 2017, 63, 870-879.	3.2	74
180	How Common Is Residual Inflammatory Risk?. <i>Circulation Research</i> , 2017, 120, 617-619.	4.5	116

#	ARTICLE	IF	CITATIONS
181	Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 133-142.	3.4	26
182	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. <i>Nature Genetics</i> , 2017, 49, 834-841.	21.4	426
183	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. <i>Nature Genetics</i> , 2017, 49, 946-952.	21.4	279
184	Cholesterol Evaluation in Young Adults: Absence of Clinical Trial Evidence Is Not a Reason to Delay Screening. <i>Annals of Internal Medicine</i> , 2017, 166, 901.	3.9	5
185	Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. <i>Nature Communications</i> , 2017, 8, 14977.	12.8	169
186	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. <i>Circulation</i> , 2017, 135, 2494-2504.	1.6	180
187	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 97-105.	11.4	298
188	Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study. <i>Human Genetics</i> , 2017, 136, 897-902.	3.8	46
189	Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism. <i>Nature Communications</i> , 2017, 8, 15539.	12.8	230
190	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	7.1	21
191	Primary Prevention With Statin Therapy in the Elderly. <i>Circulation</i> , 2017, 135, 1979-1981.	1.6	97
192	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	27.0	307
193	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	27.0	510
194	SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 981-994.	6.1	39
195	Genome-wide Trans-ethnic Meta-analysis Identifies Seven Genetic Loci Influencing Erythrocyte Traits and a Role for RBPMS in Erythropoiesis. <i>American Journal of Human Genetics</i> , 2017, 100, 51-63.	6.2	45
196	Biomarkers for Cardiovascular Screening: Progress or Pass? <i>Clinical Chemistry</i> , 2017, 63, 248-251.	3.2	5
197	Demystifying HDL Cholesterol—A “Human Knockout” to the Rescue? <i>Clinical Chemistry</i> , 2017, 63, 33-36.	3.2	5
198	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , 2017, 49, 1758-1766.	21.4	470

#	ARTICLE	IF	CITATIONS
199	Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. <i>Nature Communications</i> , 2017, 8, 910.	12.8	118
200	Effect of interleukin-1 $\beta$ inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2017, 390, 1833-1842.	13.7	948
201	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	27.0	6,227
202	Analysis of potential protein-modifying variants in 9000 endometriosis patients and 150000 controls of European ancestry. <i>Scientific Reports</i> , 2017, 7, 11380.	3.3	16
203	Unraveling Vascular Inflammation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1403-1412.	2.8	59
204	A guiding map for inflammation. <i>Nature Immunology</i> , 2017, 18, 826-831.	14.5	506
205	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	98
206	Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1257-1267.e2.	1.5	40
207	Association of High-density Lipoprotein Cholesterol Versus Apolipoprotein A $\beta$ With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer and Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	13
208	CKM <sup>Glu83Gly</sup> Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	5
209	Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very Low-density Lipoproteins. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	61
210	Lipid-Lowering and Anti-Inflammatory Benefits of Statin Therapy. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	16
211	Refining Current Scientific Priorities and Identifying New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 889-897.	1.1	6
212	Inflammation, cardiovascular disease and cancer: moving toward predictive medicine. <i>Cmaj</i> , 2017, 189, E382-E383.	2.0	8
213	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. <i>European Heart Journal</i> , 2017, 38, 3569-3575.	2.2	41
214	Canakinumab for Residual Inflammatory Risk. <i>European Heart Journal</i> , 2017, 38, 3545-3548.	2.2	34
215	Genome-wide association meta-analysis of fish and EPA+DHA consumption in 17 US and European cohorts. <i>PLoS ONE</i> , 2017, 12, e0186456.	2.5	18
216	Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. <i>PLoS Medicine</i> , 2017, 14, e1002383.	8.4	341

#	ARTICLE	IF	CITATIONS
217	Perspectives from NHLBI Global Health Think Tank Meeting for Late Stage (T4) Translation Research. Global Heart, 2017, 12, 341.	2.3	11
218	Genome-wide physical activity interactions in adiposity • A meta-analysis of 200,452 adults. PLoS Genetics, 2017, 13, e1006528.	3.5	158
219	Ranking and characterization of established BMI and lipid associated loci as candidates for gene-environment interactions. PLoS Genetics, 2017, 13, e1006812.	3.5	24
220	Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study. PLoS ONE, 2017, 12, e0167742.	2.5	29
221	Genome-Wide Association Study for Incident Myocardial Infarction and Coronary Heart Disease in Prospective Cohort Studies: The CHARGE Consortium. PLoS ONE, 2016, 11, e0144997.	2.5	69
222	An Empirical Comparison of Joint and Stratified Frameworks for Studying G × E Interactions: Systolic Blood Pressure and Smoking in the CHARGE Gene×Lifestyle Interactions Working Group. Genetic Epidemiology, 2016, 40, 404-415.	1.3	18
223	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.2	28
224	Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease. Annals of Internal Medicine, 2016, 165, 786.	3.9	120
225	The Pooled Cohort Equations 3 Years On. Circulation, 2016, 134, 1789-1791.	1.6	34
226	Circulating N-linked Glycoprotein Side-chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. Journal of the American Heart Association, 2016, 5, .	3.7	44
227	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. American Heart Journal, 2016, 178, 135-144.	2.7	58
228	Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. European Heart Journal, 2016, 37, 2428-2437.	2.2	200
229	Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2016, 15, 695-707.	10.2	130
230	Monoclonal antibodies targeting PCSK9 and the search for prolonged duration of effect. European Heart Journal, 2016, 37, 1370-1372.	2.2	1
231	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 136.	6.1	53
232	Physical and neurobehavioral determinants of reproductive onset and success. Nature Genetics, 2016, 48, 617-623.	21.4	158
233	Lipid biomarkers and long-term risk of cancer in the Women's Health Study. American Journal of Clinical Nutrition, 2016, 103, 1397-1407.	4.7	117
234	Catechol-O-methyltransferase association with hemoglobin A1c. Metabolism: Clinical and Experimental, 2016, 65, 961-967.	3.4	14



#	ARTICLE	IF	CITATIONS
235	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 840-849.	11.4	159
236	<i>KLB</i> is associated with alcohol drinking, and its gene product $\beta$ -Klotho is necessary for FGF21 regulation of alcohol preference. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14372-14377.	7.1	208
237	A principal component meta-analysis on multiple anthropometric traits identifies novel loci for body shape. <i>Nature Communications</i> , 2016, 7, 13357.	12.8	74
238	Fish consumption, fish oils, and cardiovascular events: still waiting for definitive evidence. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 951-952.	4.7	3
239	Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. <i>Nature Genetics</i> , 2016, 48, 1162-1170.	21.4	223
240	The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. <i>Nature Genetics</i> , 2016, 48, 1171-1184.	21.4	362
241	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet</i> , 2016, 388, 2532-2561.	13.7	1,399
242	Is Statin Monotherapy the Perfect Polypill?. <i>Circulation</i> , 2016, 134, 91-93.	1.6	3
243	Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2349-2358.	27.0	979
244	Informative Neutral Studies Matter—Why the Targeting Inflammation With Salsalate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention. <i>JAMA Cardiology</i> , 2016, 1, 423.	6.1	3
245	Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature Genetics</i> , 2016, 48, 1462-1472.	21.4	284
246	How to translate clinical trial results into gain in healthy life expectancy for individual patients. <i>BMJ</i> , 2016, 352, i1548.	6.0	44
247	Neighborhood Socioeconomic Status in Relation to Serum Biomarkers in the Black Women's Health Study. <i>Journal of Urban Health</i> , 2016, 93, 279-291.	3.6	28
248	Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. <i>Nature Genetics</i> , 2016, 48, 856-866.	21.4	520
249	Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. <i>American Journal of Hypertension</i> , 2016, 29, 1117-1124.	2.0	13
250	Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy. <i>American Journal of Cardiology</i> , 2016, 118, 49-55.	1.6	5
251	Interaction of methylation-related genetic variants with circulating fatty acids on plasma lipids: a meta-analysis of 7 studies and methylation analysis of 3 studies in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 567-578.	4.7	24
252	Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. <i>Circulation Research</i> , 2016, 118, 1106-1115.	4.5	97



#	ARTICLE	IF	CITATIONS
253	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. <i>Science</i> , 2016, 351, 1166-1171.	12.6	438
254	Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. <i>European Heart Journal</i> , 2016, 37, 1720-1722.	2.2	188
255	Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?. <i>Circulation Research</i> , 2016, 118, 607-619.	4.5	28
256	A Test in Context. <i>Journal of the American College of Cardiology</i> , 2016, 67, 712-723.	2.8	258
257	Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. <i>Nature Communications</i> , 2016, 7, 10494.	12.8	153
258	Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. <i>American Journal of Cardiology</i> , 2016, 117, 376-381.	1.6	10
259	Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. <i>Nature Communications</i> , 2016, 7, 10023.	12.8	412
260	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. <i>European Heart Journal</i> , 2016, 37, 1373-1379.	2.2	180
261	From C-Reactive Protein to Interleukin-6 to Interleukin-1. <i>Circulation Research</i> , 2016, 118, 145-156.	4.5	680
262	Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. <i>Nature Genetics</i> , 2016, 48, 189-194.	21.4	211
263	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. <i>Human Molecular Genetics</i> , 2016, 25, 358-370.	2.9	73
264	Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. <i>European Heart Journal</i> , 2016, 37, 554-560.	2.2	80
265	Identifying Novel Gene Variants in Coronary Artery Disease and Shared Genes With Several Cardiovascular Risk Factors. <i>Circulation Research</i> , 2016, 118, 83-94.	4.5	52
266	Rare, low frequency and common coding variants in CHRNA5 and their contribution to nicotine dependence in European and African Americans. <i>Molecular Psychiatry</i> , 2016, 21, 601-607.	7.9	32
267	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. <i>PLoS ONE</i> , 2016, 11, e0165615.	2.5	31
268	Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. <i>Blood</i> , 2015, 126, e19-e29.	1.4	55
269	Plasma Inflammatory Markers and the Risk of Developing Hypertension in Men. <i>Journal of the American Heart Association</i> , 2015, 4, e001802.	3.7	39
270	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. <i>PLoS Genetics</i> , 2015, 11, e1005378.	3.5	331

#	ARTICLE	IF	CITATIONS
271	Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1544-1550.	2.4	105
272	Using genetics to test the causal relationship of total adiposity and periodontitis: Mendelian randomization analyses in the Gene-Lifestyle Interactions and Dental Endpoints (GLIDE) Consortium. International Journal of Epidemiology, 2015, 44, 638-650.	1.9	54
273	Rare coding variants and X-linked loci associated with age at menarche. Nature Communications, 2015, 6, 7756.	12.8	32
274	Genome wide association study identifies variants in NBEA associated with migraine in bipolar disorder. Journal of Affective Disorders, 2015, 172, 453-461.	4.1	15
275	Stimulating High Impact HIV-Related Cardiovascular Research. Journal of the American College of Cardiology, 2015, 65, 738-744.	2.8	17
276	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	27.8	1,328
277	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	27.8	3,823
278	Genetic loci associated with circulating phospholipid trans fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. American Journal of Clinical Nutrition, 2015, 101, 398-406.	4.7	49
279	Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nature Communications, 2015, 6, 5897.	12.8	173
280	Dietary fatty acids modulate associations between genetic variants and circulating fatty acids in plasma and erythrocyte membranes: Meta-analysis of nine studies in the CHARGE consortium. Molecular Nutrition and Food Research, 2015, 59, 1373-1383.	3.3	37
281	Vitamin D-Associated Genetic Variation and Risk of Breast Cancer in the Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 627-630.	2.5	20
282	Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nature Genetics, 2015, 47, 284-290.	21.4	1,285
283	Genetic loci associated with circulating levels of very long-chain saturated fatty acids. Journal of Lipid Research, 2015, 56, 176-184.	4.2	38
284	Cardiovascular risks associated with incident and prevalent periodontal disease. Journal of Clinical Periodontology, 2015, 42, 21-28.	4.9	96
285	Is Venous Thromboembolism a Chronic Inflammatory Disease?. Clinical Chemistry, 2015, 61, 313-316.	3.2	18
286	Comparing Cardiovascular Risk Prediction Scores. Annals of Internal Medicine, 2015, 162, 313-314.	3.9	24
287	A Proposal to Incorporate Trial Data Into a Hybrid ACC/AHA Algorithm for the Allocation of Statin Therapy in Primary Prevention. Journal of the American College of Cardiology, 2015, 65, 942-948.	2.8	21
288	Directional dominance on stature and cognition in diverse human populations. Nature, 2015, 523, 459-462.	27.8	173

#	ARTICLE	IF	CITATIONS
289	Plasma C-Reactive Protein and Risk of Breast Cancer in Two Prospective Studies and a Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1199-1206.	2.5	44
290	Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 519-526.	1.8	41
291	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. <i>Clinical Chemistry</i> , 2015, 61, 1156-1163.	3.2	53
292	JCL Roundtable: Is inflammation a future target in preventing arteriosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 119-128.	1.5	10
293	Prospective Study of Plasma Homocysteine Level and Risk of Age-Related Macular Degeneration in Women. <i>Ophthalmic Epidemiology</i> , 2015, 22, 85-93.	1.7	12
294	Is the adiposity-associated <i>FTO</i> gene variant related to all-cause mortality independent of adiposity? Meta-analysis of data from 169,551 Caucasian adults. <i>Obesity Reviews</i> , 2015, 16, 327-340.	6.5	8
295	High-Sensitivity Cardiac Troponin I and B-Type Natriuretic Peptide as Predictors of Vascular Events in Primary Prevention. <i>Circulation</i> , 2015, 131, 1851-1860.	1.6	113
296	Statin Therapy and Risk of Fracture. <i>JAMA Internal Medicine</i> , 2015, 175, 171.	5.1	53
297	Meta-analysis of 65,734 Individuals Identifies TSPAN15 and SLC44A2 as Two Susceptibility Loci for Venous Thromboembolism. <i>American Journal of Human Genetics</i> , 2015, 96, 532-542.	6.2	222
298	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. <i>Lancet</i> , 2015, 385, 2264-2271.	13.7	564
299	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	2.2	126
300	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. <i>Circulation</i> , 2015, 131, 2061-2069.	1.6	145
301	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015, 47, 1294-1303.	21.4	357
302	Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo. <i>Circulation</i> , 2015, 132, 2220-2229.	1.6	101
303	Association Between High-Sensitivity C-Reactive Protein and Total Stroke by Hypertensive Status Among Men. <i>Journal of the American Heart Association</i> , 2015, 4, e002073.	3.7	26
304	Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 688-695.	5.1	6
305	Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. <i>Nature</i> , 2015, 526, 112-117.	27.8	483
306	A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. <i>Nature Genetics</i> , 2015, 47, 1121-1130.	21.4	2,054

#	ARTICLE	IF	CITATIONS
307	Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Tj ETQq1 1 0.784314 rgBT /Qyerlock 10	1.6	12
308	Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart, 2015, 101, 369-376.	2.9	41
309	Genome-wide association study of kidney function decline in individuals of European descent. Kidney International, 2015, 87, 1017-1029.	5.2	113
310	Genome-wide Studies of Verbal Declarative Memory in Nondemented Older People: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Biological Psychiatry, 2015, 77, 749-763.	1.3	67
311	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Molecular Psychiatry, 2015, 20, 647-656.	7.9	235
312	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	13.7	562
313	A Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians. PLoS ONE, 2015, 10, e0120758.	2.5	323
314	No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects. PLoS ONE, 2014, 9, e111156.	2.5	8
315	Response to Letter Regarding Article, "Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in) Tj ETQq1 1 0.784314 rgBT /Qyerlock 10	1.6	12
316	Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study. BMJ, The, 2014, 349, g5334-g5334.	6.0	46
317	Selectivity in Genetic Association with Sub-classified Migraine in Women. PLoS Genetics, 2014, 10, e1004366.	3.5	45
318	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	12.8	216
319	A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events. Journal of the American Heart Association, 2014, 3, e001221.	3.7	179
320	Targeting inflammatory pathways for the treatment of cardiovascular disease. European Heart Journal, 2014, 35, 540-543.	2.2	62
321	Response to Comment on the Reports of Over-estimation of ASCVD Risk Using the 2013 AHA/ACC Risk Equation. Circulation, 2014, 129, 268-269.	1.6	18
322	Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events. Circulation, 2014, 129, 553-561.	1.6	189
323	Comparison of Lifestyle-Based and Traditional Cardiovascular Disease Prediction in a Multiethnic Cohort of Nonsmoking Women. Circulation, 2014, 130, 1466-1473.	1.6	19
324	FTO genetic variants, dietary intake and body mass index: insights from 177 330 individuals. Human Molecular Genetics, 2014, 23, 6961-6972.	2.9	143

#	ARTICLE	IF	CITATIONS
325	Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies. American Journal of Epidemiology, 2014, 179, 621-632.	3.4	47
326	Glycated Hemoglobin Measurement and Prediction of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2014, 311, 1225.	7.4	179
327	DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. Human Molecular Genetics, 2014, 23, 2490-2497.	2.9	56
328	Further Insight Into the Cardiovascular Risk Calculator. JAMA Internal Medicine, 2014, 174, 1964.	5.1	148
329	Formulation of Treatment Recommendations for Statins—Reply. JAMA - Journal of the American Medical Association, 2014, 311, 306.	7.4	1
330	Plasma Levels of the Proinflammatory Chitinase-Binding Glycoprotein YKL-40, Variation in the Chitinase 3-Like 1 Gene ( <i>CHI3L1</i> ), and Incident Cardiovascular Events. Journal of the American Heart Association, 2014, 3, e000897.	3.7	44
331	Predisposing Factors Associated With Development of Persistent Compared With Paroxysmal Atrial Fibrillation. Journal of the American Heart Association, 2014, 3, e000916.	3.7	69
332	Effects of an Antisense Oligonucleotide Inhibitor of C-reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers. Journal of the American Heart Association, 2014, 3, .	3.7	33
333	Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci. American Journal of Human Genetics, 2014, 94, 349-360.	6.2	158
334	Pleiotropic genes for metabolic syndrome and inflammation. Molecular Genetics and Metabolism, 2014, 112, 317-338.	1.1	107
335	Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. European Heart Journal, 2014, 35, 837-843.	2.2	54
336	An assessment by the Statin Diabetes Safety Task Force: 2014 update. Journal of Clinical Lipidology, 2014, 8, S17-S29.	1.5	102
337	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. European Heart Journal, 2014, 35, 2242-2248.	2.2	42
338	Anti-inflammatory therapies for cardiovascular disease. European Heart Journal, 2014, 35, 1782-1791.	2.2	469
339	Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. Clinical Pharmacology and Therapeutics, 2014, 95, 314-320.	4.7	12
340	Inactivating Mutations in <i>NPC1L1</i> and Protection from Coronary Heart Disease. New England Journal of Medicine, 2014, 371, 2072-2082.	27.0	386
341	Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk. Circulation, 2014, 129, 635-642.	1.6	338
342	B-Type Natriuretic Peptides Improve Cardiovascular Disease Risk Prediction in a Cohort of Women. Journal of the American College of Cardiology, 2014, 64, 1789-1797.	2.8	25

#	ARTICLE	IF	CITATIONS
343	Response to Letter Regarding Article, "High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy" Circulation, 2014, 129, e481.	1.6	0
344	Inflammation, C-Reactive Protein, and Cardiovascular Disease. Circulation Research, 2014, 114, 594-595.	4.5	40
345	Gene-Age Interactions in Blood Pressure Regulation: A Large-Scale Investigation with the CHARGE, Global BPgen, and ICBP Consortia. American Journal of Human Genetics, 2014, 95, 24-38.	6.2	109
346	Effects of Long-Term Averaging of Quantitative Blood Pressure Traits on the Detection of Genetic Associations. American Journal of Human Genetics, 2014, 95, 49-65.	6.2	73
347	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	27.8	548
348	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. Journal of the American College of Cardiology, 2014, 64, 485-494.	2.8	512
349	Polymorphisms in Catechol- <i>O</i> -Methyltransferase Modify Treatment Effects of Aspirin on Risk of Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2160-2167.	2.4	35
350	LDL cholesterol: controversies and future therapeutic directions. Lancet, The, 2014, 384, 607-617.	13.7	229
351	Common Genetic Variations in the Vitamin D Pathway in Relation to Blood Pressure. American Journal of Hypertension, 2014, 27, 1387-1395.	2.0	33
352	Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30Âmg/dl) With Rosuvastatin 20Âmg Daily (from JUPITER). American Journal of Cardiology, 2014, 114, 1682-1689.	1.6	53
353	Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186.	21.4	1,818
354	Refining the American guidelines for prevention of cardiovascular disease " Authors' reply. Lancet, The, 2014, 383, 600.	13.7	47
355	Plasma Pentraxin 3 Levels Do Not Predict Coronary Events but Reflect Metabolic Disorders in Patients with Coronary Artery Disease in the CARE Trial. PLoS ONE, 2014, 9, e94073.	2.5	16
356	A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature, 2013, 502, 377-380.	27.8	197
357	Genome-wide Association Analysis of Blood-Pressure Traits in African-Ancestry Individuals Reveals Common Associated Genes in African and Non-African Populations. American Journal of Human Genetics, 2013, 93, 545-554.	6.2	189
358	Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. American Heart Journal, 2013, 166, 199-207.e15.	2.7	347
359	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	21.4	2,641
360	Common variants associated with plasma triglycerides and risk for coronary artery disease. Nature Genetics, 2013, 45, 1345-1352.	21.4	754

#	ARTICLE	IF	CITATIONS
361	Statins: new American guidelines for prevention of cardiovascular disease. <i>Lancet</i> , The, 2013, 382, 1762-1765.	13.7	443
362	A Genome-Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. <i>Genetic Epidemiology</i> , 2013, 37, 512-521.	1.3	99
363	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. <i>Circulation</i> , 2013, 128, 1504-1512.	1.6	162
364	Loci influencing blood pressure identified using a cardiovascular gene-centric array. <i>Human Molecular Genetics</i> , 2013, 22, 1663-1678.	2.9	141
365	A Trial-Based Approach to Statin Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1123.	7.4	48
366	Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. <i>Nature Genetics</i> , 2013, 45, 145-154.	21.4	675
367	Inflammation, Coronary Flow Reserve, and Microvascular Dysfunction. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 668-671.	5.3	38
368	Common Variants in Mendelian Kidney Disease Genes and Their Association with Renal Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 2105-2117.	6.1	33
369	Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 668-676.	4.7	161
370	Genetic variation of fifteen folate metabolic pathway associated gene loci and the risk of incident head and neck carcinoma: The Women's Genome Health Study. <i>Clinica Chimica Acta</i> , 2013, 418, 33-36.	1.1	6
371	Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. <i>American Heart Journal</i> , 2013, 165, 1008-1014.	2.7	80
372	Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 295.	4.8	72
373	Biomarkers and functional outcomes from ischaemic cerebral events in women: a prospective cohort study. <i>European Journal of Neurology</i> , 2013, 20, 375-381.	3.3	7
374	Prospective Evaluation of B-type Natriuretic Peptide Concentrations and the Risk of Type 2 Diabetes in Women. <i>Clinical Chemistry</i> , 2013, 59, 557-565.	3.2	26
375	Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. <i>Nature Genetics</i> , 2013, 45, 501-512.	21.4	578
376	Genome-wide meta-analysis identifies new susceptibility loci for migraine. <i>Nature Genetics</i> , 2013, 45, 912-917.	21.4	338
377	Novel genetic markers improve measures of atrial fibrillation risk prediction. <i>European Heart Journal</i> , 2013, 34, 2243-2251.	2.2	127
378	C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care. <i>European Heart Journal</i> , 2013, 34, 1258-1261.	2.2	34



#	ARTICLE	IF	CITATIONS
379	Sex-stratified Genome-wide Association Studies Including 270,000 Individuals Show Sexual Dimorphism in Genetic Loci for Anthropometric Traits. <i>PLoS Genetics</i> , 2013, 9, e1003500.	3.5	371
380	Gene $\times$ Physical Activity Interactions in Obesity: Combined Analysis of 111,421 Individuals of European Ancestry. <i>PLoS Genetics</i> , 2013, 9, e1003607.	3.5	168
381	A Prospective Study of Circulating C-Reactive Protein, Interleukin-6, and Tumor Necrosis Factor $\alpha$ Receptor 2 Levels and Risk of Ovarian Cancer. <i>American Journal of Epidemiology</i> , 2013, 178, 1256-1264.	3.4	85
382	A genome-wide association study of early menopause and the combined impact of identified variants. <i>Human Molecular Genetics</i> , 2013, 22, 1465-1472.	2.9	104
383	Multiethnic Meta-Analysis of Genome-Wide Association Studies in $>100,000$ Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease. <i>Circulation</i> , 2013, 128, 1310-1324.	1.6	128
384	Association of Adiposity Genetic Variants With Menarche Timing in 92,105 Women of European Descent. <i>American Journal of Epidemiology</i> , 2013, 178, 451-460.	3.4	51
385	Novel locus including FGF21 is associated with dietary macronutrient intake. <i>Human Molecular Genetics</i> , 2013, 22, 1895-1902.	2.9	167
386	High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy. <i>Circulation</i> , 2013, 128, 1189-1197.	1.6	203
387	High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 2485-2493.	1.6	38
388	Expanding Options for Scientific Publication. <i>Circulation</i> , 2013, 127, 155-156.	1.6	7
389	Sugar-Sweetened Beverages and Genetic Risk of Obesity. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 211-213.	0.4	8
390	Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?. <i>Transactions of the American Clinical and Climatological Association</i> , 2013, 124, 174-90.	0.5	60
391	Genome-Wide Association Study Evaluating Lipoprotein-Associated Phospholipase A <sub>2</sub> Mass and Activity at Baseline and After Rosuvastatin Therapy. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 676-685.	5.1	33
392	Physical Activity and Inflammation in a Multiethnic Cohort of Women. <i>Medicine and Science in Sports and Exercise</i> , 2012, 44, 1088-1096.	0.4	24
393	Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function. <i>PLoS Genetics</i> , 2012, 8, e1002584.	3.5	166
394	High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. <i>European Heart Journal</i> , 2012, 33, 531-537.	2.2	101
395	What Works and in Whom?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 592-593.	2.2	10
396	Lipoprotein(a), Ethnicity, and Cardiovascular Risk. <i>Circulation</i> , 2012, 125, 207-209.	1.6	4

#	ARTICLE	IF	CITATIONS
397	Tomato-Based Food Products Are Related to Clinically Modest Improvements in Selected Coronary Biomarkers in Women., Journal of Nutrition, 2012, 142, 326-333.	2.9	37
398	Hyperlipidemia as an Instigator of Inflammation: Inaugurating New Approaches to Vascular Prevention. Journal of the American Heart Association, 2012, 1, 3-5.	3.7	20
399	Lipid-Modifying Therapies and Risk of Pancreatitis. JAMA - Journal of the American Medical Association, 2012, 308, 804.	7.4	140
400	Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Human Molecular Genetics, 2012, 21, 5329-5343.	2.9	64
401	Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction. Circulation: Cardiovascular Genetics, 2012, 5, 257-264.	5.1	231
402	Association of LDL Cholesterol, Nonâ€“HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. JAMA - Journal of the American Medical Association, 2012, 307, 1302.	7.4	650
403	Plasma Adiponectin and the Risk of Hypertension in White and Black Postmenopausal Women. Clinical Chemistry, 2012, 58, 1438-1445.	3.2	12
404	C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. New England Journal of Medicine, 2012, 367, 1310-1320.	27.0	909
405	Clinical Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Disease Prediction in a Multiethnic Cohort of Women. Clinical Chemistry, 2012, 58, 1352-1363.	3.2	27
406	Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial. Clinical Chemistry, 2012, 58, 183-189.	3.2	133
407	Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein. Circulation: Cardiovascular Genetics, 2012, 5, 58-65.	5.1	33
408	Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. International Journal of Epidemiology, 2012, 41, 1419-1433.	1.9	230
409	Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet, The, 2012, 379, 1205-1213.	13.7	668
410	Coronary artery calcium for guiding statin treatment. Lancet, The, 2012, 379, 311-312.	13.7	2
411	Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet, The, 2012, 380, 565-571.	13.7	691
412	Effects of Interleukin-1Î² Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen. Circulation, 2012, 126, 2739-2748.	1.6	481
413	A genome-wide analysis of 'Bounty' descendants implicates several novel variants in migraine susceptibility. Neurogenetics, 2012, 13, 261-266.	1.4	32
414	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 2012, 44, 491-501.	21.4	1,100

#	ARTICLE	IF	CITATIONS
415	Sugar-Sweetened Beverages and Genetic Risk of Obesity. <i>New England Journal of Medicine</i> , 2012, 367, 1387-1396.	27.0	517
416	FTO genotype is associated with phenotypic variability of body mass index. <i>Nature</i> , 2012, 490, 267-272.	27.8	383
417	Therapeutic Targeting of Inflammation in Atherosclerosis: We Are Getting Closer. <i>Canadian Journal of Cardiology</i> , 2012, 28, 619-622.	1.7	11
418	Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER Trial. <i>Clinical Chemistry</i> , 2012, 58, 877-886.	3.2	64
419	Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. <i>Nature Genetics</i> , 2012, 44, 260-268.	21.4	303
420	On-Treatment Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1521-1528.	2.8	90
421	Coronary Artery Calcium Scanning Should be Used for Primary Prevention. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 111-118.	5.3	22
422	Genome-wide Linkage and Association Analyses Implicate FASN in Predisposition to Uterine Leiomyomata. <i>American Journal of Human Genetics</i> , 2012, 91, 621-628.	6.2	83
423	Meta-analysis identifies six new susceptibility loci for atrial fibrillation. <i>Nature Genetics</i> , 2012, 44, 670-675.	21.4	533
424	Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative. <i>Circulation</i> , 2012, 125, 1748-1756.	1.6	205
425	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. <i>Human Molecular Genetics</i> , 2012, 21, 5373-5384.	2.9	168
426	An X Chromosome Association Scan of the Norfolk Island Genetic Isolate Provides Evidence for a Novel Migraine Susceptibility Locus at Xq12. <i>PLoS ONE</i> , 2012, 7, e37903.	2.5	11
427	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. <i>Thrombosis and Haemostasis</i> , 2012, 107, 232-240.	3.4	62
428	Relation of Renal Function to Risk for Incident Atrial Fibrillation in Women. <i>American Journal of Cardiology</i> , 2012, 109, 538-542.	1.6	27
429	Comparison of associations of adherence to a Dietary Approaches to Stop Hypertension (DASH)-style diet with risks of cardiovascular disease and venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 189-198.	3.8	58
430	Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels. <i>Circulation</i> , 2011, 123, 731-738.	1.6	461
431	Genome-wide association study reveals three susceptibility loci for common migraine in the general population. <i>Nature Genetics</i> , 2011, 43, 695-698.	21.4	355
432	Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1666-1675.	2.8	206

#	ARTICLE	IF	CITATIONS
433	Interleukin-1 $\beta$ inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal, 2011, 162, 597-605.	2.7	728
434	Islet amyloid polypeptide gene variation (IAPP) and the risk of incident type 2 diabetes mellitus: The women's genome health study. Clinica Chimica Acta, 2011, 412, 785-787.	1.1	3
435	Genetic variants in eleven telomere-associated genes and the risk of incident cardio/cerebrovascular disease: The Women's Genome Health Study. Clinica Chimica Acta, 2011, 412, 199-202.	1.1	23
436	Mitochondrial uncoupling protein gene cluster variation (UCP2&Ucp3) and the risk of incident type 2 diabetes mellitus: The Women's Genome Health Study. Atherosclerosis, 2011, 214, 107-109.	0.8	12
437	Genetic variants of 11 telomere-pathway gene loci and the risk of incident type 2 diabetes mellitus: The Women's Genome Health Study. Atherosclerosis, 2011, 218, 144-146.	0.8	28
438	Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet, The, 2011, 377, 1085-1095.	13.7	941
439	Geographic Variation in Cardiovascular Inflammation among Healthy Women in the Women's Health Study. PLoS ONE, 2011, 6, e27468.	2.5	8
440	Author Response. Clinical Trials, 2011, 8, 430-431.	1.6	0
441	Smoking, Smoking Cessation, and Risk for Symptomatic Peripheral Artery Disease in Women. Annals of Internal Medicine, 2011, 154, 719.	3.9	79
442	Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels. Annals of Internal Medicine, 2011, 155, 742.	3.9	52
443	Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473, 317-325.	27.8	3,058
444	Longitudinal Assessment of Estimated Glomerular Filtration Rate in Apparently Healthy Adults: A Post hoc Analysis from the JUPITER Study (Justification for the Use of Statins in Prevention: An) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 50 297 Td		
445	The Editor's Roundtable: JUPITER Follow-Up. American Journal of Cardiology, 2011, 107, 1549-1557.	1.6	2
446	Relation of Interleukin-6 and Vascular Cellular Adhesion Molecule-1 Levels to Functional Decline in Patients With Lower Extremity Peripheral Arterial Disease. American Journal of Cardiology, 2011, 107, 1392-1398.	1.6	22
447	Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease. American Journal of Cardiology, 2011, 108, 1362-1370.	1.6	448
448	C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment. Cancer Prevention Research, 2011, 4, 1172-1180.	1.5	26
449	Effect of Rosuvastatin on Hemoglobin Levels in Patients With Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial. Journal of Clinical Pharmacology, 2011, 51, 1483-1487.	2.0	7
450	Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk &lt;5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. European Heart Journal, 2011, 32, 75-83.	2.2	36

#	ARTICLE	IF	CITATIONS
451	The relative importance of systolic versus diastolic blood pressure control and incident symptomatic peripheral artery disease in women. <i>Vascular Medicine</i> , 2011, 16, 239-246.	1.5	14
452	Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 312-317.	5.1	48
453	Physical Activity Modifies the Effect of <i>LPL</i> , <i>LIPC</i> , and <i>CETP</i> Polymorphisms on HDL-C Levels and the Risk of Myocardial Infarction in Women of European Ancestry. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 74-80.	5.1	34
454	Association of Variation at the <i>ABO</i> Locus With Circulating Levels of Soluble Intercellular Adhesion Molecule-1, Soluble P-selectin, and Soluble E-selectin. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 681-686.	5.1	77
455	Association of Hypertension Drug Target Genes With Blood Pressure and Hypertension in 86 588 Individuals. <i>Hypertension</i> , 2011, 57, 903-910.	2.7	181
456	Circulating Inflammatory and Endothelial Markers and Risk of Hypertension in White and Black Postmenopausal Women. <i>Clinical Chemistry</i> , 2011, 57, 729-736.	3.2	27
457	Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus. <i>Circulation</i> , 2011, 123, 2811-2818.	1.6	106
458	Lifestyle Interaction With Fat Mass and Obesity-Associated ( <i>FTO</i> ) Genotype and Risk of Obesity in Apparently Healthy U.S. Women. <i>Diabetes Care</i> , 2011, 34, 675-680.	8.6	84
459	Coronary Artery Calcium Scanning in Primary Prevention. <i>Archives of Internal Medicine</i> , 2011, 171, 2051.	3.8	3
460	High-Sensitivity C-Reactive Protein, Vascular Imaging, and Vulnerable Plaque. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 195-197.	2.6	11
461	Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. <i>European Heart Journal</i> , 2011, 32, 2962-2969.	2.2	36
462	HMG CoA Reduction in Patients with Average Cholesterol Concentrations. <i>Clinical Chemistry</i> , 2011, 57, 1072-1073.	3.2	2
463	High-Molecular-Weight and Total Adiponectin Levels and Incident Symptomatic Peripheral Artery Disease in Women. <i>Circulation</i> , 2011, 124, 2303-2311.	1.6	45
464	A tale of three labels: translating the JUPITER trial data into regulatory claims. <i>Clinical Trials</i> , 2011, 8, 417-422.	1.6	3
465	Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. <i>Nature Genetics</i> , 2011, 43, 1005-1011.	21.4	403
466	Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals Novel Associations at the <i>NFKB1K</i> , <i>PNPLA3</i> , <i>RELA</i> , and <i>SH2B3</i> Loci. <i>PLoS Genetics</i> , 2011, 7, e1001374.	3.5	76
467	Hemoglobin A1c, Body Mass Index, and the Risk of Hypertension in Women. <i>American Journal of Hypertension</i> , 2011, 24, 328-334.	2.0	22
468	Physical Activity Attenuates the Influence of <i>FTO</i> Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children. <i>PLoS Medicine</i> , 2011, 8, e1001116.	8.4	446

#	ARTICLE	IF	CITATIONS
469	Genetic Determinants of Cardiovascular Events among Women with Migraine: A Genome-Wide Association Study. PLoS ONE, 2011, 6, e22106.	2.5	20
470	Socioeconomic Status and Incident Type 2 Diabetes Mellitus: Data from the Women's Health Study. PLoS ONE, 2011, 6, e27670.	2.5	81
471	Psoriasis, inflammation, and vascular risk: a problem more than skin deep?. European Heart Journal, 2010, 31, 902-904.	2.2	21
472	Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial. Annals of Internal Medicine, 2010, 152, 488.	3.9	198
473	A large-scale candidate gene association study of age at menarche and age at natural menopause. Human Genetics, 2010, 128, 515-527.	3.8	114
474	Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome. Metabolism: Clinical and Experimental, 2010, 59, 54-61.	3.4	52
475	Comparison of Effects of Statin Use on Mortality in Patients With Peripheral Arterial Disease With Versus Without Elevated C-Reactive Protein and D-Dimer Levels. American Journal of Cardiology, 2010, 105, 1348-1352.	1.6	24
476	Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). American Journal of Cardiology, 2010, 106, 204-209.	1.6	136
477	AJC Editor's Consensus: Rheumatoid Arthritis and Atherosclerotic Cardiovascular Disease. American Journal of Cardiology, 2010, 106, 442-447.	1.6	19
478	The JUPITER Trial: Responding to the Critics. American Journal of Cardiology, 2010, 106, 1351-1356.	1.6	29
479	Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of Thrombosis and Haemostasis, 2010, 8, 95-100.	3.8	65
480	A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans. Clinical Pharmacology and Therapeutics, 2010, 87, 445-451.	4.7	85
481	Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466, 707-713.	27.8	3,249
482	Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature, 2010, 467, 832-838.	27.8	1,789
483	New loci associated with kidney function and chronic kidney disease. Nature Genetics, 2010, 42, 376-384.	21.4	710
484	Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nature Genetics, 2010, 42, 949-960.	21.4	836
485	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948.	21.4	2,634
486	Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nature Genetics, 2010, 42, 1077-1085.	21.4	445



#	ARTICLE	IF	CITATIONS
487	Statin Therapy for Low-LDL, High-hsCRP Patients: From JUPITER to CORONA. <i>Clinical Chemistry</i> , 2010, 56, 505-507.	3.2	9
488	Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 447-452.	2.2	52
489	Lipoprotein(a) and Risk of Type 2 Diabetes. <i>Clinical Chemistry</i> , 2010, 56, 1252-1260.	3.2	165
490	Genome-Wide Association Study Identifies Variants at the <i>IL18</i> <i>BCO2</i> Locus Associated With Interleukin-18 Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 885-890.	2.4	74
491	Association Between a Literature-Based Genetic Risk Score and Cardiovascular Events in Women. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 631.	7.4	320
492	Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein. <i>Circulation</i> , 2010, 121, 143-150.	1.6	157
493	Gamma-glutamyl carboxylase and its influence on warfarin dose. <i>Thrombosis and Haemostasis</i> , 2010, 104, 750-754.	3.4	53
494	Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women. <i>Diabetes</i> , 2010, 59, 1153-1160.	0.6	157
495	Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. <i>Human Molecular Genetics</i> , 2010, 19, 2706-2715.	2.9	178
496	Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. <i>Circulation</i> , 2010, 121, 1069-1077.	1.6	287
497	Variation in Recovery. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 684-693.	2.2	94
498	Establishing a Clinical Basis for hsCRP in the Prevention and Treatment of Cardiovascular Disease. <i>Clinical Chemistry</i> , 2010, 56, 1186-1187.	3.2	8
499	Multiple Genetic Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular Disease Risk Factors. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 523-530.	5.1	285
500	On the Use of Variance per Genotype as a Tool to Identify Quantitative Trait Interaction Effects: A Report from the Women's Genome Health Study. <i>PLoS Genetics</i> , 2010, 6, e1000981.	3.5	175
501	A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. <i>European Heart Journal</i> , 2010, 31, 1730-1736.	2.2	140
502	Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1266-1273.	2.8	191
503	The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2319-2327.	2.8	419
504	Biomarkers in peripheral arterial disease patients and near- and longer-term mortality. <i>Journal of Vascular Surgery</i> , 2010, 52, 85-90.	1.1	43



#	ARTICLE	IF	CITATIONS
505	The Fat-Mass and Obesity-Associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. <i>American Heart Journal</i> , 2010, 160, 1163-1169.	2.7	51
506	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet</i> , The, 2010, 376, 333-339.	13.7	221
507	HDL cholesterol and residual risk of first cardiovascular events – Authors' reply. <i>Lancet</i> , The, 2010, 376, 1738-1739.	13.7	2
508	Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 465-469.	1.3	5
509	Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations. <i>PLoS ONE</i> , 2010, 5, e9763.	2.5	205
510	Inflammation, high-sensitivity C-reactive protein, and vascular protection. <i>Texas Heart Institute Journal</i> , 2010, 37, 40-1.	0.3	7
511	Statin therapy for elevated hsCRP: what are the public health implications?. <i>American Journal of Managed Care</i> , 2010, 16, 561-2.	1.1	0
512	Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 616-623.	2.2	128
513	A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2009, 360, 1851-1861.	27.0	657
514	Metabolic Syndrome, Inflammation, and Risk of Symptomatic Peripheral Artery Disease in Women. <i>Circulation</i> , 2009, 120, 1041-1047.	1.6	66
515	Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study. <i>Clinical Chemistry</i> , 2009, 55, 305-312.	3.2	82
516	Population-Based Genomewide Genetic Analysis of Common Clinical Chemistry Analytes. <i>Clinical Chemistry</i> , 2009, 55, 39-51.	3.2	13
517	C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease. <i>Clinical Chemistry</i> , 2009, 55, 209-215.	3.2	156
518	Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 424-430.	2.4	136
519	An Evaluation of Candidate Genes of Inflammation and Thrombosis in Relation to the Risk of Venous Thromboembolism. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 57-62.	5.1	36
520	Response to Letter Regarding Article, “Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events” <i>Circulation</i> , 2009, 119, .	1.6	4
521	A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women. <i>Diabetes Care</i> , 2009, 32, 3-8.	8.6	66
522	Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. <i>European Heart Journal</i> , 2009, 30, 1378-1384.	2.2	75

#	ARTICLE	IF	CITATIONS
523	Gene Variation of the Transient Receptor Potential Cation Channel, Subfamily M, Member 7 ( ) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	2.6	20
524	Comparison of LDL Cholesterol Concentrations by Friedewald Calculation and Direct Measurement in Relation to Cardiovascular Events in 27 331 Women. Clinical Chemistry, 2009, 55, 888-894.	3.2	153
525	Myocardial Infarction in a 72-Year-Old Woman with Low LDL-C and Increased hsCRP: Implications for Statin Therapy. Clinical Chemistry, 2009, 55, 369-374.	3.2	4
526	Polymorphism in the <i>CETP</i> Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction. Circulation: Cardiovascular Genetics, 2009, 2, 26-33.	5.1	186
527	GOSR2 Lys67Arg Is Associated With Hypertension in Whites. American Journal of Hypertension, 2009, 22, 163-168.	2.0	14
528	A Common Variant at 9p21 Is Associated With Sudden and Arrhythmic Cardiac Death. Circulation, 2009, 120, 2062-2068.	1.6	67
529	Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2009, 302, 1186.	7.4	99
530	The JUPITER Trial. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 279-285.	2.2	119
531	Novel Loci, Including Those Related to Crohn Disease, Psoriasis, and Inflammation, Identified in a Genome-Wide Association Study of Fibrinogen in 17 686 Women. Circulation: Cardiovascular Genetics, 2009, 2, 134-141.	5.1	76
532	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). Journal of Thrombosis and Haemostasis, 2009, 7, 332-339.	3.8	252
533	The Editor's Roundtable: The JUPITER Trialâ€™Initial Results and Clinical Implications. American Journal of Cardiology, 2009, 103, 1417-1425.	1.6	19
534	Should patients with rheumatoid arthritis receive statin therapy?. Arthritis and Rheumatism, 2009, 60, 1205-1209.	6.7	21
535	Moving toward new statin guidelines in a post-JUPITER world: Principles to consider. Current Atherosclerosis Reports, 2009, 11, 249-256.	4.8	18
536	Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nature Genetics, 2009, 41, 724-728.	21.4	348
537	Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. Journal of Thrombosis and Haemostasis, 2009, 7, 588-596.	3.8	35
538	Association Between Polymorphisms in the Î²2â€œadrenoceptor Gene and Migraine in Women. Headache, 2009, 49, 235-244.	3.9	13
539	Population Analysis of Large Copy Number Variants and Hotspots of Human Genetic Disease. American Journal of Human Genetics, 2009, 84, 148-161.	6.2	530
540	Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women. Circulation, 2009, 119, 931-939.	1.6	427

#	ARTICLE	IF	CITATIONS
541	Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach. <i>Clinica Chimica Acta</i> , 2009, 402, 189-192.	1.1	18
542	Association of shorter mean telomere length with risk of incident myocardial infarction: A prospective, nested caseâ€“control approach. <i>Clinica Chimica Acta</i> , 2009, 403, 139-141.	1.1	77
543	Mean telomere length and risk of incident venous thromboembolism: A prospective, nested caseâ€“control approach. <i>Clinica Chimica Acta</i> , 2009, 406, 148-150.	1.1	6
544	Prediction of Incident Hypertension Risk in Women with Currently Normal Blood Pressure. <i>American Journal of Medicine</i> , 2009, 122, 464-471.	1.5	52
545	<i>The American Journal of Cardiology</i> and <i>Journal of Periodontology</i> Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. <i>Journal of Periodontology</i> , 2009, 80, 1021-1032.	3.4	221
546	Novel Associations of CPS1, MUT, NOX4, and DPEP1 With Plasma Homocysteine in a Healthy Population. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 142-150.	5.1	96
547	A Meta-Analysis of Candidate Gene Polymorphisms and Ischemic Stroke in 6 Study Populations. <i>Stroke</i> , 2009, 40, 683-695.	2.0	115
548	Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. <i>Atherosclerosis</i> , 2009, 202, 282-288.	0.8	39
549	Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. <i>Atherosclerosis</i> , 2009, 203, 371-376.	0.8	167
550	Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis. <i>Diabetes Care</i> , 2009, 32, 1924-1929.	8.6	369
551	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. <i>Lancet, The</i> , 2009, 373, 1175-1182.	13.7	886
552	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial â€“ Authors' reply. <i>Lancet, The</i> , 2009, 374, 26-27.	13.7	2
553	Inflammation in Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2129-2138.	2.8	1,738
554	Reduction in C-Reactive Protein and Low-Density Lipoprotein Cholesterol and Cardiovascular Event Rates After Initiation of Rosuvastatin: A Prospective Study of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin Trial. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 596-597.	0.4	0
555	Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures. <i>Annals of Internal Medicine</i> , 2009, 150, 795.	3.9	416
556	Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3. <i>Annals of Internal Medicine</i> , 2009, 150, 65.	3.9	225
557	Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide Analysis. <i>PLoS Genetics</i> , 2009, 5, e1000730.	3.5	300
558	Association between polymorphisms in the beta2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women. <i>Thrombosis and Haemostasis</i> , 2009, 101, 351-8.	3.4	11

#	ARTICLE	IF	CITATIONS
559	Pharmacogenetic factors affecting INR control during warfarin initiation. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 98-98.	2.1	0
560	HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. <i>Diabetologia</i> , 2008, 51, 267-275.	6.3	53
561	Using inflammatory biomarkers to guide lipid therapy. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 29-34.	2.0	3
562	Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 326-331.	4.7	743
563	Circulating Blood Markers and Functional Impairment in Peripheral Arterial Disease. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1504-1510.	2.6	54
564	Migraine and Biomarkers of Cardiovascular Disease in Women. <i>Cephalalgia</i> , 2008, 28, 49-56.	3.9	106
565	Renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms are not associated with the risk of incident type 2 diabetes mellitus: a prospective cohort study. <i>Journal of Internal Medicine</i> , 2008, 263, 376-385.	6.0	13
566	The Editor's Roundtable: Psoriasis, Inflammation, and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2008, 101, 1119-1126.	1.6	30
567	AJC Editor's Consensus: Psoriasis and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2008, 102, 1631-1643.	1.6	148
568	Dietary glycemic index, dietary glycemic load, blood lipids, and C-reactive protein. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 437-443.	3.4	178
569	A Kinesin Family Member 6 Variant Is Associated With Coronary Heart Disease in the Women's Health Study. <i>Journal of the American College of Cardiology</i> , 2008, 51, 444-448.	2.8	102
570	Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2008, 52, 124-131.	2.8	84
571	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. <i>New England Journal of Medicine</i> , 2008, 359, 2195-2207.	27.0	5,712
572	Loci Related to Metabolic-Syndrome Pathways Including LEPR, HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women's Genome Health Study. <i>American Journal of Human Genetics</i> , 2008, 82, 1185-1192.	6.2	299
573	Polymorphisms of the HNF1A Gene Encoding Hepatocyte Nuclear Factor-1 $\alpha$ are Associated with C-Reactive Protein. <i>American Journal of Human Genetics</i> , 2008, 82, 1193-1201.	6.2	170
574	Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: A prespecified subgroup analysis of a community-based, randomized, open-label trial. <i>Clinical Therapeutics</i> , 2008, 30, 661-672.	2.5	32
575	Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: A prospective analysis of the Women's Health Study. <i>Atherosclerosis</i> , 2008, 197, 297-302.	0.8	19
576	Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. <i>Atherosclerosis</i> , 2008, 197, 694-699.	0.8	40

#	ARTICLE	IF	CITATIONS
577	C-reactive protein gene variation and type 2 diabetes mellitus: A case-control study. <i>Atherosclerosis</i> , 2008, 197, 931-936.	0.8	33
578	Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in Southeastern New England. <i>Atherosclerosis</i> , 2008, 200, 221-227.	0.8	24
579	Genetic variants within the interleukin-1 gene cluster, and risk of incident myocardial infarction, and ischemic stroke: A nested case-control approach. <i>Atherosclerosis</i> , 2008, 201, 124-129.	0.8	26
580	Symptomatic Peripheral Arterial Disease in Women. <i>Circulation</i> , 2008, 117, 823-831.	1.6	122
581	Risk of type 2 diabetes mellitus in those with hypertension: reply. <i>European Heart Journal</i> , 2008, 29, 953-954.	2.2	0
582	Genetic Variation of the Androgen Receptor and Risk of Myocardial Infarction and Ischemic Stroke in Women. <i>Stroke</i> , 2008, 39, 1590-1592.	2.0	16
583	Inflammation, C-Reactive Protein, and Atherothrombosis. <i>Journal of Periodontology</i> , 2008, 79, 1544-1551.	3.4	217
584	High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care. <i>Clinical Chemistry</i> , 2008, 54, 234-237.	3.2	40
585	Plasma Concentration of Heat Shock Protein 27 and Risk of Cardiovascular Disease: A Prospective, Nested Case-Control Study. <i>Clinical Chemistry</i> , 2008, 54, 139-146.	3.2	38
586	Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events. <i>Circulation</i> , 2008, 118, 993-1001.	1.6	366
587	C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction. <i>Circulation</i> , 2008, 118, 2243-2251.	1.6	743
588	Rationale, Design, and Methodology of the Women's Genome Health Study: A Genome-Wide Association Study of More Than 25 000 Initially Healthy American Women. <i>Clinical Chemistry</i> , 2008, 54, 249-255.	3.2	167
589	Fasting versus Nonfasting Triglycerides and the Prediction of Cardiovascular Risk: Do We Need to Revisit the Oral Triglyceride Tolerance Test?. <i>Clinical Chemistry</i> , 2008, 54, 11-13.	3.2	265
590	Novel Association of ABO Histo-Blood Group Antigen with Soluble ICAM-1: Results of a Genome-Wide Association Study of 6,578 Women. <i>PLoS Genetics</i> , 2008, 4, e1000118.	3.5	289
591	Novel Association of HK1 with Glycated Hemoglobin in a Non-Diabetic Population: A Genome-Wide Evaluation of 14,618 Participants in the Women's Genome Health Study. <i>PLoS Genetics</i> , 2008, 4, e1000312.	3.5	87
592	Tracing Sub-Structure in the European American Population with PCA-Informative Markers. <i>PLoS Genetics</i> , 2008, 4, e1000114.	3.5	60
593	Can Fishing for New Genes Catch Patients at Risk of Coronary Artery Disease?. <i>Clinical Chemistry</i> , 2008, 54, 453-455.	3.2	1
594	Genetic Loci Associated With Plasma Concentration of Low-Density Lipoprotein Cholesterol, High-Density Lipoprotein Cholesterol, Triglycerides, Apolipoprotein A1, and Apolipoprotein B Among 6382 White Women in Genome-Wide Analysis With Replication. <i>Circulation: Cardiovascular Genetics</i> , 2008, 1, 21-30.	5.1	117

#	ARTICLE	IF	CITATIONS
595	Response: Re: C-Reactive Protein and Risk of Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 444-445.	6.3	5
596	Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial. Diabetes Care, 2008, 31, 2338-2343.	8.6	84
597	Genetic Variants of Tumor Necrosis Factor Superfamily, Member 4 (TNFSF4), and Risk of Incident Atherothrombosis and Venous Thromboembolism. Clinical Chemistry, 2008, 54, 833-840.	3.2	23
598	Response to Letter Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women's Health Study" Circulation, 2008, 117, .	1.6	0
599	Performance of Commercial Platforms for Rapid Genotyping of Polymorphisms Affecting Warfarin Dose. American Journal of Clinical Pathology, 2008, 129, 876-883.	0.7	74
600	The Time for Cardiovascular Inflammation Reduction Trials Has Arrived. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1222-1224.	2.4	23
601	Biomarkers of Inflammation and Thrombosis as Predictors of Near-Term Mortality in Patients with Peripheral Arterial Disease: A Cohort Study. Annals of Internal Medicine, 2008, 148, 85.	3.9	123
602	Circulating Levels of Endothelial Adhesion Molecules and Risk of Diabetes in an Ethnically Diverse Cohort of Women. Diabetes, 2007, 56, 1898-1904.	0.6	129
603	Comparison of Interleukin-6 and C-Reactive Protein for the Risk of Developing Hypertension in Women. Hypertension, 2007, 49, 304-310.	2.7	141
604	Homocysteine, 5,10-Methylenetetrahydrofolate Reductase 677C>T Polymorphism, Nutrient Intake, and Incident Cardiovascular Disease in 24 968 Initially Healthy Women. Clinical Chemistry, 2007, 53, 845-851.	3.2	62
605	C-Reactive Protein and Risk of Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 890-894.	6.3	84
606	Polymorphisms and Haplotypes of the Estrogen Receptor- $\beta$ Gene (ESR2) and Cardiovascular Disease in Men and Women. Clinical Chemistry, 2007, 53, 1749-1756.	3.2	75
607	Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism. Circulation, 2007, 116, 1497-1503.	1.6	117
608	Natriuretic Peptide Precursor A Gene Polymorphisms and Risk of Blood Pressure Progression and Incident Hypertension. Hypertension, 2007, 50, 1114-1119.	2.7	33
609	Intercellular Adhesion Molecule 1 (ICAM1) Lys56Met and Gly241Arg Gene Variants, Plasma-Soluble ICAM1 Concentrations, and Risk of Incident Cardiovascular Events in 23 014 Initially Healthy White Women. Stroke, 2007, 38, 3152-3157.	2.0	12
610	Two Common Gene Variants on Chromosome 9 and Risk of Atherothrombosis. Stroke, 2007, 38, e111.	2.0	20
611	Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. Circulation, 2007, 115, 1528-1536.	1.6	316
612	Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women. JAMA - Journal of the American Medical Association, 2007, 297, 611.	7.4	1,529



#	ARTICLE	IF	CITATIONS
613	Nonfasting Triglycerides and Cardiovascular Risk—Reply. JAMA - Journal of the American Medical Association, 2007, 298, 2004.	7.4	1
614	Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women. JAMA - Journal of the American Medical Association, 2007, 298, 309.	7.4	1,326
615	Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism. Annals of Internal Medicine, 2007, 147, 525.	3.9	66
616	Response to Letter Regarding Article, “Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events” Circulation, 2007, 115, .	1.6	0
617	Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. American Heart Journal, 2007, 154, 1043-1051.	2.7	58
618	Hemoglobin A1c Predicts Diabetes but Not Cardiovascular Disease in Nondiabetic Women. American Journal of Medicine, 2007, 120, 720-727.	1.5	169
619	Physical Activity and Reduced Risk of Cardiovascular Events. Circulation, 2007, 116, 2110-2118.	1.6	799
620	Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study. European Heart Journal, 2007, 28, 2937-2943.	2.2	153
621	Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. Journal of Vascular Surgery, 2007, 45, 2-9.	1.1	141
622	Atherosclerosis. Journal of the American College of Cardiology, 2007, 49, 1589-1599.	2.8	63
623	C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk. Journal of the American College of Cardiology, 2007, 49, 2129-2138.	2.8	520
624	Elevated Levels of Inflammation, D-Dimer, and Homocysteine Are Associated With Adverse Calf Muscle Characteristics and Reduced Calf Strength in Peripheral Arterial Disease. Journal of the American College of Cardiology, 2007, 50, 897-905.	2.8	70
625	Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC—Norfolk Prospective Population Study. Journal of Internal Medicine, 2007, 262, 678-689.	6.0	74
626	Relation Between Soluble Intercellular Adhesion Molecule-1, Homocysteine, and Fibrinogen Levels and Race/Ethnicity in Women Without Cardiovascular Disease. American Journal of Cardiology, 2007, 99, 1246-1251.	1.6	23
627	Comparison of Characteristics of Future Myocardial Infarctions in Women With Baseline High Versus Baseline Low Levels of High-Sensitivity C-Reactive Protein. American Journal of Cardiology, 2007, 99, 1500-1503.	1.6	8
628	Comparison of Usefulness of Body Mass Index Versus Metabolic Risk Factors in Predicting 10-Year Risk of Cardiovascular Events in Women. American Journal of Cardiology, 2007, 100, 1654-1658.	1.6	108
629	Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. American Journal of Cardiology, 2007, 100, 1659-1664.	1.6	113
630	Genetic determinants of C-reactive protein. Current Atherosclerosis Reports, 2007, 9, 195-203.	4.8	32



#	ARTICLE	IF	CITATIONS
631	Awareness, Accuracy, and Predictive Validity of Self-Reported Cholesterol in Women. <i>Journal of General Internal Medicine</i> , 2007, 22, 606-613.	2.6	29
632	Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity. <i>Nutrition Reviews</i> , 2007, 65, S253-S259.	5.8	117
633	Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. <i>Journal of Clinical Investigation</i> , 2007, 117, 746-756.	8.2	825
634	Biomarkers for prediction of cardiovascular events. <i>New England Journal of Medicine</i> , 2007, 356, 1472-3; author reply 1474-5.	27.0	11
635	Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: A nested case-control study. <i>Atherosclerosis</i> , 2006, 187, 332-335.	0.8	46
636	C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. <i>Journal of the American College of Cardiology</i> , 2006, 47, C19-C31.	2.8	295
637	Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected Siblings. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1803-1810.	2.8	82
638	Inflammation and Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2006, 48, A33-A46.	2.8	157
639	The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2235-2242.	2.8	109
640	Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1473-1480.	3.4	88
641	Sex Hormone-Binding Globulin and Serum Testosterone are Inversely Associated with C-Reactive Protein Levels in Postmenopausal Women at High Risk for Cardiovascular Disease. <i>Annals of Epidemiology</i> , 2006, 16, 105-112.	1.9	55
642	A Prospective Assessment of the Y402H Variant in Complement Factor H, Genetic Variants in C-Reactive Protein, and Risk of Age-Related Macular Degeneration. , 2006, 47, 2336.		70
643	The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women. <i>Annals of Internal Medicine</i> , 2006, 145, 21.	3.9	445
644	Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1363.	7.4	183
645	Lack of Association Between Genetic Variation in 9 Innate Immunity Genes and Baseline CRP Levels. <i>Annals of Human Genetics</i> , 2006, 70, 574-586.	0.8	7
646	Influence of Genetic Variation in the C-Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia. <i>Annals of Human Genetics</i> , 2006, 70, 705-716.	0.8	61
647	Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 341-348.	3.8	46
648	D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1208-1214.	3.8	74

#	ARTICLE	IF	CITATIONS
649	Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1718-1722.	3.8	35
650	A prospective replication study of five gene variants previously associated with risk of myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2093-2095.	3.8	15
651	Hormonal factors and risk of recurrent venous thrombosis: the Prevention of Recurrent Venous Thromboembolism trial. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2199-2203.	3.8	78
652	Increased inflammatory markers in children with familial hypercholesterolaemia. <i>European Journal of Clinical Investigation</i> , 2006, 36, 147-152.	3.4	43
653	Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. <i>Genes and Immunity</i> , 2006, 7, 211-219.	4.1	51
654	Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 71-76.	2.1	24
655	Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2270.	7.4	249
656	Genetic Variants of Arachidonate 5-Lipoxygenase-Activating Protein, and Risk of Incident Myocardial Infarction and Ischemic Stroke. <i>Stroke</i> , 2006, 37, 2007-2011.	2.0	95
657	Polymorphisms of the Phosphodiesterase 4D, cAMP-Specific ( <i>PDE4D</i> ) Gene and Risk of Ischemic Stroke. <i>Stroke</i> , 2006, 37, 2012-2017.	2.0	50
658	Polymorphisms in the Advanced Glycosylation End Product-Specific Receptor Gene and Risk of Incident Myocardial Infarction or Ischemic Stroke. <i>Stroke</i> , 2006, 37, 1686-1690.	2.0	37
659	Aspirin Has A Gender-Dependent Impact on Antiinflammatory 15-Epi-Lipoxin A 4 Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, e14-7.	2.4	66
660	Association of Adiponectin Gene Variations with Risk of Incident Myocardial Infarction and Ischemic Stroke: A Nested Case-Control Study. <i>Clinical Chemistry</i> , 2006, 52, 2021-2027.	3.2	55
661	Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events. <i>Circulation</i> , 2006, 113, 2278-2284.	1.6	309
662	C-Reactive Protein as a Risk Predictor. <i>Circulation</i> , 2006, 114, e67-74.	1.6	68
663	Polymorphism in the $\beta_2$ -Adrenergic Receptor and Lipoprotein Lipase Genes as Risk Determinants for Idiopathic Venous Thromboembolism. <i>Circulation</i> , 2006, 113, 2193-2200.	1.6	39
664	Impact of Traditional and Novel Risk Factors on the Relationship Between Socioeconomic Status and Incident Cardiovascular Events. <i>Circulation</i> , 2006, 114, 2619-2626.	1.6	207
665	Association of Physical Activity and Body Mass Index With Novel and Traditional Cardiovascular Biomarkers in Women. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1412.	7.4	331
666	Incomplete Financial Disclosure for Study of Funding and Outcomes in Major Cardiovascular Trials. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2720.	7.4	3

#	ARTICLE	IF	CITATIONS
667	Risk Factors for Progression of Peripheral Arterial Disease in Large and Small Vessels. <i>Circulation</i> , 2006, 113, 2623-2629.	1.6	234
668	Valsartan, Blood Pressure Reduction, and C-Reactive Protein. <i>Hypertension</i> , 2006, 48, 73-79.	2.7	133
669	A Prospective Study of Hemoglobin A1c Concentrations and Risk of Breast Cancer in Women. <i>Cancer Research</i> , 2006, 66, 2869-2875.	0.9	31
670	Inflammation in Systemic Vascular Disease: What Can We Learn?. <i>Advances in Pulmonary Hypertension</i> , 2006, 5, 15-16.	0.1	0
671	INFLAMMATION AND NEUROLOGICAL DISEASE. CONTINUUM Lifelong Learning in Neurology, 2005, 11, 114-118.	0.8	0
672	C-Reactive Protein Levels Are Not Associated with Increased Risk for Colorectal Cancer in Women. <i>Annals of Internal Medicine</i> , 2005, 142, 425.	3.9	108
673	Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2819-2821.	3.8	11
674	Association of Common <i>CRP</i> Gene Variants with CRP Levels and Cardiovascular Events. <i>Annals of Human Genetics</i> , 2005, 69, 623-638.	0.8	199
675	D-Dimer and Inflammatory Markers as Predictors of Functional Decline in Men and Women with and without Peripheral Arterial Disease. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1688-1696.	2.6	50
676	Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 977-987.	46.4	760
677	Association Between Consumption of Beer, Wine, and Liquor and Plasma Concentration of High-Sensitivity C-Reactive Protein in Women Aged 39 to 89 Years. <i>American Journal of Cardiology</i> , 2005, 96, 83-88.	1.6	26
678	Comparison of Usefulness of Inflammatory Markers in Patients With Versus Without Peripheral Arterial Disease in Predicting Adverse Cardiovascular Outcomes (Myocardial Infarction, Stroke, and) <i>TJ ETQq0 0 0 rgBT /Overlook 10 Tf 5</i>	0.1	0
679	Interaction between inflammation-related gene polymorphisms and cigarette smoking on the risk of myocardial infarction in the Physician's Health Study. <i>Human Genetics</i> , 2005, 118, 287-294.	3.8	32
680	307-S: Magnesium Intake, C-Reactive Protein, and the Prevalence of Metabolic Syndrome in Middle-Aged and Older us Women. <i>American Journal of Epidemiology</i> , 2005, 161, S77-S77.	3.4	0
681	Effect of Intensive Glycemic Control on Levels of Markers of Inflammation in Type 1 Diabetes Mellitus in the Diabetes Control and Complications Trial. <i>Circulation</i> , 2005, 111, 2446-2453.	1.6	95
682	Haplotype Analysis of the $\beta 2$ Adrenergic Receptor Gene and Risk of Myocardial Infarction in Humans. <i>Genetics</i> , 2005, 169, 1583-1587.	2.9	28
683	Pharmacogenetics: the outlook for genetic testing in statin therapy. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 2-3.	3.3	3
684	Should Age and Time Be Eliminated From Cardiovascular Risk Prediction Models?. <i>Circulation</i> , 2005, 111, 657-658.	1.6	36

#	ARTICLE	IF	CITATIONS
685	Dietary Calcium, Vitamin D, and the Prevalence of Metabolic Syndrome in Middle-Aged and Older U.S. Women. <i>Diabetes Care</i> , 2005, 28, 2926-2932.	8.6	385
686	Magnesium Intake, C-Reactive Protein, and the Prevalence of Metabolic Syndrome in Middle-Aged and Older U.S. Women. <i>Diabetes Care</i> , 2005, 28, 1438-1444.	8.6	255
687	Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 56.	7.4	974
688	Toll-like Receptor 4 <i>&lt;i&gt;Asp299Gly&lt;/i&gt;</i> Gene Polymorphism and Risk of Atherothrombosis. <i>Stroke</i> , 2005, 36, 154-157.	2.0	69
689	Low-Dose Aspirin in the Primary Prevention of Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 47.	7.4	704
690	Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 326.	7.4	639
691	Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. <i>Atherosclerosis</i> , 2005, 178, 139-145.	0.8	124
692	Tryptophanyl-tRNA synthetase gene polymorphisms and risk of incident myocardial infarction. <i>Atherosclerosis</i> , 2005, 181, 137-141.	0.8	2
693	The effect of statin therapy on lipoprotein associated phospholipase A2 levels. <i>Atherosclerosis</i> , 2005, 182, 193-198.	0.8	90
694	C-reactive protein comes of age. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 29-36.	3.3	187
695	Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. <i>American Heart Journal</i> , 2005, 150, 109-115.	2.7	34
696	C-Reactive Protein Levels and Outcomes after Statin Therapy. <i>New England Journal of Medicine</i> , 2005, 352, 20-28.	27.0	2,103
697	Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1644-1648.	2.8	219
698	Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1417-1424.	2.8	113
699	A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. <i>New England Journal of Medicine</i> , 2005, 352, 1293-1304.	27.0	1,801
700	Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. <i>Thrombosis and Haemostasis</i> , 2005, 93, 1108-1116.	3.4	34
701	C-Reactive Protein and Risk for Colorectal Cancer. <i>Annals of Internal Medicine</i> , 2005, 143, 544.	3.9	0
702	Use of Pharmacogenetics and Clinical Factors To Predict the Maintenance Dose of Warfarin.. <i>Blood</i> , 2005, 106, 550-550.	1.4	5

#	ARTICLE	IF	CITATIONS
703	C-reactive protein, inflammation, and cardiovascular disease: clinical update. Texas Heart Institute Journal, 2005, 32, 384-6.	0.3	59
704	Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15178-15183.	7.1	252
705	Atherosclerotic Vascular Disease Conference. Circulation, 2004, 109, 2613-2616.	1.6	85
706	Perspective on Selected Issues in Cardiovascular Disease Research With a Focus on Black Americans. Circulation, 2004, 110, e7-12.	1.6	22
707	Blood Pressure and Risk of Secondary Cardiovascular Events in Women. Circulation, 2004, 109, 1623-1629.	1.6	42
708	Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?. Circulation, 2004, 109, 2818-2825.	1.6	578
709	Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women. Circulation, 2004, 109, 726-732.	1.6	379
710	Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians' Health Study. Clinical Chemistry, 2004, 50, 1364-1371.	3.2	107
711	Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores. Circulation, 2004, 109, 1955-1959.	1.6	446
712	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Circulation, 2004, 110, e550-3.	1.6	94
713	Prospective Evaluation of the Alcohol Dehydrogenase 1*1/1*2 Gene Polymorphism and Risk of Stroke. Stroke, 2004, 35, e39-42.	2.0	7
714	Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events. Circulation, 2004, 109, IV-6-IV-19.	1.6	313
715	Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal Women. Circulation, 2004, 110, 292-300.	1.6	50
716	Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 628-636.	2.4	89
717	C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis. Journal of Thrombosis and Haemostasis, 2004, 2, 1240-1243.	3.8	15
718	Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes. Journal of Thrombosis and Haemostasis, 2004, 2, 1034-1037.	3.8	18
719	Inflammatory and Thrombotic Blood Markers and Walking-Related Disability in Men and Women with and Without Peripheral Arterial Disease. Journal of the American Geriatrics Society, 2004, 52, 1888-1894.	2.6	25
720	Effect of physical activity on serum C-reactive protein. American Journal of Cardiology, 2004, 93, 221-225.	1.6	151

#	ARTICLE	IF	CITATIONS
721	C-Reactive protein levels among women of various ethnic groups living in the United States (from the Tj ETQq1 1 0.784314 rgBT /Overl	1.6	231
722	Tree and spline based association analysis of gene-gene interaction models for ischemic stroke. Statistics in Medicine, 2004, 23, 1439-1453.	1.6	139
723	Effect of sleep loss on C-Reactive protein, an inflammatory marker of cardiovascular risk. Journal of the American College of Cardiology, 2004, 43, 678-683.	2.8	1,001
724	High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. American Heart Journal, 2004, 148, S19-S26.	2.7	235
725	Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction. JAMA - Journal of the American Medical Association, 2004, 291, 2821.	7.4	407
726	Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. Atherosclerosis, 2004, 175, 91-94.	0.8	49
727	High-sensitivity C-reactive protein: clinical importance. Current Problems in Cardiology, 2004, 29, 439-93.	2.4	257
728	Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. The American Heart Hospital Journal, 2004, 2, 4-9.	0.2	29
729	Connecting the role of C-reactive protein and statins in cardiovascular disease. Clinical Cardiology, 2003, 26, 39-44.	1.8	43
730	C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. Current Atherosclerosis Reports, 2003, 5, 341-349.	4.8	93
731	Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients. American Journal of Cardiology, 2003, 91, 1120-1123.	1.6	21
732	High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. American Journal of Cardiology, 2003, 92, 17-22.	1.6	207
733	C-reactive protein, inflammation, and coronary risk. Cardiology Clinics, 2003, 21, 315-325.	2.2	160
734	Erratum to "A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men". Atherosclerosis, 2003, 166, 415.	0.8	3
735	A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis, 2003, 166, 323-329.	0.8	33
736	C-reactive protein and other inflammatory risk markers in acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, S37-S42.	2.8	299
737	Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. American Journal of Medicine, 2003, 114, 438-444.	1.5	57
738	Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. American Journal of Medicine, 2003, 114, 485-494.	1.5	44



#	ARTICLE	IF	CITATIONS
739	Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention. <i>Circulation</i> , 2003, 107, 363-369.	1.6	2,100
740	C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events. <i>Circulation</i> , 2003, 107, 391-397.	1.6	2,145
741	Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. <i>Atherosclerosis</i> , 2003, 171, 351-358.	0.8	19
742	Relationship of total and abdominal adiposity with CRP and IL-6 in women. <i>Annals of Epidemiology</i> , 2003, 13, 674-682.	1.9	218
743	Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>Circulation</i> , 2003, 108, 2292-2297.	1.6	412
744	From Vulnerable Plaque to Vulnerable Patient. <i>Circulation</i> , 2003, 108, 1664-1672.	1.6	2,308
745	Sex Hormone Levels and Risk of Cardiovascular Events in Postmenopausal Women. <i>Circulation</i> , 2003, 108, 1688-1693.	1.6	223
746	From Vulnerable Plaque to Vulnerable Patient. <i>Circulation</i> , 2003, 108, 1772-1778.	1.6	1,562
747	Alcohol Consumption and Plasma Concentration of C-Reactive Protein. <i>Circulation</i> , 2003, 107, 443-447.	1.6	305
748	Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States: Implication for Clinical Interpretation. <i>Clinical Chemistry</i> , 2003, 49, 666-669.	3.2	171
749	Blood Pressure, C-Reactive Protein, and Risk of Future Cardiovascular Events. <i>Circulation</i> , 2003, 108, 2993-2999.	1.6	297
750	C-Reactive Protein and the Risk of Developing Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2945.	7.4	828
751	Antioxidant Vitamins C and E Improve Endothelial Function in Children With Hyperlipidemia. <i>Circulation</i> , 2003, 108, 1059-1063.	1.6	214
752	Statin Use and Leg Functioning in Patients With and Without Lower-Extremity Peripheral Arterial Disease. <i>Circulation</i> , 2003, 107, 757-761.	1.6	205
753	C-Reactive Protein. <i>Circulation</i> , 2003, 108, e81-5.	1.6	327
754	Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score. <i>Circulation</i> , 2003, 108, 161-165.	1.6	240
755	C-reactive Protein Concentration Distribution among US Children and Young Adults: Findings from the National Health and Nutrition Examination Survey, 1999-2000. <i>Clinical Chemistry</i> , 2003, 49, 1353-1357.	3.2	130
756	Alanine for Proline Substitution in the Peroxisome Proliferator-Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 859-863.	2.4	100



#	ARTICLE	IF	CITATIONS
757	Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. <i>Human Molecular Genetics</i> , 2003, 13, 389-396.	2.9	85
758	Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2003, 348, 1425-1434.	27.0	771
759	D-Dimer, Inflammatory Markers, and Lower Extremity Functioning in Patients With and Without Peripheral Arterial Disease. <i>Circulation</i> , 2003, 107, 3191-3198.	1.6	105
760	Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial. <i>European Heart Journal</i> , 2003, 24, 1843-1847.	2.2	23
761	Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. <i>Current Opinion in Cardiology</i> , 2003, 18, 471-478.	1.8	82
762	C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 650-655.	2.4	182
763	Soluble CD40 Ligand Levels Indicate Lipid Accumulation in Carotid Atheroma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, e11-4.	2.4	70
764	Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. <i>New England Journal of Medicine</i> , 2002, 347, 1557-1565.	27.0	3,201
765	Soluble Intercellular Adhesion Molecule-1, Soluble Vascular Adhesion Molecule-1, and the Development of Symptomatic Peripheral Arterial Disease in Men. <i>Circulation</i> , 2002, 106, 820-825.	1.6	202
766	Tumour necrosis factor- $\alpha$ , inflammatory biomarkers, and atherogenesis. <i>European Heart Journal</i> , 2002, 23, 345-347.	2.2	23
767	C-Reactive Protein, Subclinical Atherosclerosis, and Risk of Cardiovascular Events. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1512-1513.	2.4	48
768	Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women. <i>Circulation</i> , 2002, 106, 1930-1937.	1.6	359
769	Inflammatory Biomarkers, Statins, and the Risk of Stroke. <i>Circulation</i> , 2002, 105, 2583-2585.	1.6	54
770	Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 980.	7.4	582
771	C-reactive protein and prognosis after percutaneous coronary intervention. <i>European Heart Journal</i> , 2002, 23, 923-925.	2.2	16
772	Inflammatory markers and coronary heart disease. <i>Current Opinion in Lipidology</i> , 2002, 13, 383-389.	2.7	91
773	Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. <i>American Journal of Clinical Nutrition</i> , 2002, 75, 492-498.	4.7	516
774	Inflammation, Cell Adhesion Molecules, and Stroke: Tools in Pathophysiology and Epidemiology?. <i>Stroke</i> , 2002, 33, 2141-2143.	2.0	40

#	ARTICLE	IF	CITATIONS
775	Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. European Heart Journal, 2002, 23, 831-834.	2.2	172
776	C-Reactive Protein, Statins, and the Primary Prevention of Atherosclerotic Cardiovascular Disease. Preventive Cardiology, 2002, 5, 42-46.	1.1	18
777	Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels. Journal of the American College of Cardiology, 2002, 40, 49-55.	2.8	41
778	A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis, 2002, 161, 469-474.	0.8	81
779	Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis, 2002, 162, 217-219.	0.8	191
780	Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1668-1673.	2.4	397
781	Blood Levels of Long-Chain n-3 Fatty Acids and the Risk of Sudden Death. New England Journal of Medicine, 2002, 346, 1113-1118.	27.0	1,029
782	Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet, The, 2002, 359, 2159-2163.	13.7	235
783	Inflammation and Atherosclerosis. Circulation, 2002, 105, 1135-1143.	1.6	6,191
784	Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac Death. Circulation, 2002, 105, 2595-2599.	1.6	480
785	A Prospective Evaluation of the CD14 and CD18 Gene Polymorphisms and Risk of Stroke. Stroke, 2002, 33, 892-895.	2.0	22
786	Is C-Reactive Protein Specific for Vascular Disease in Women?. Annals of Internal Medicine, 2002, 136, 529.	3.9	72
787	Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. American Journal of Cardiology, 2002, 89, 216-221.	1.6	50
788	Relation between markers of systemic vascular inflammation and smoking in women. American Journal of Cardiology, 2002, 89, 1117-1119.	1.6	332
789	Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. American Journal of Cardiology, 2002, 89, 1133-1135.	1.6	61
790	Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. American Journal of Cardiology, 2002, 89, 1205-1207.	1.6	84
791	Inherited risk factors for venous thromboembolism: Implications for clinical practice. Clinical Cornerstone, 2002, 4, 18-30.	0.7	13
792	Inflammatory biomarkers and cardiovascular risk prediction. Journal of Internal Medicine, 2002, 252, 283-294.	6.0	583

#	ARTICLE	IF	CITATIONS
793	On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. <i>Circulation</i> , 2002, 105, 2-4.	1.6	25
794	Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. <i>Circulation</i> , 2002, 105, 1776-9.	1.6	16
795	A prospective evaluation of the heat shock protein 70 gene polymorphisms and the risk of stroke. <i>Thrombosis and Haemostasis</i> , 2002, 87, 622-5.	3.4	0
796	Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. <i>Clinical Chemistry</i> , 2002, 48, 1781-4.	3.2	40
797	A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. <i>Atherosclerosis</i> , 2001, 154, 699-702.	0.8	59
798	G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. <i>Journal of the American College of Cardiology</i> , 2001, 37, 215-218.	2.8	86
799	Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. <i>Journal of the American College of Cardiology</i> , 2001, 37, 445-450.	2.8	249
800	C-reactive protein and electron beam computed tomography: a perfect match?: reply. <i>Journal of the American College of Cardiology</i> , 2001, 37, 972.	2.8	0
801	A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1302-1306.	2.8	208
802	The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design. <i>American Heart Journal</i> , 2001, 141, 893-898.	2.7	54
803	High-Sensitivity C-Reactive Protein. <i>Circulation</i> , 2001, 103, 1813-1818.	1.6	1,223
804	Role of inflammatory biomarkers in prediction of coronary heart disease. <i>Lancet</i> , The, 2001, 358, 946-948.	13.7	122
805	A Prospective Study of <i>Helicobacter pylori</i> Seropositivity and the Risk for Future Myocardial Infarction among Socioeconomically Similar U.S. Men. <i>Annals of Internal Medicine</i> , 2001, 135, 184.	3.9	70
806	Soluble CD40L and Cardiovascular Risk in Women. <i>Circulation</i> , 2001, 104, 2266-2268.	1.6	429
807	Novel Clinical Markers of Vascular Wall Inflammation. <i>Circulation Research</i> , 2001, 89, 763-771.	4.5	663
808	Effect of marathon running on inflammatory and hemostatic markers. <i>American Journal of Cardiology</i> , 2001, 88, 918-920.	1.6	119
809	Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. <i>American Journal of Cardiology</i> , 2001, 88, 1264-1269.	1.6	221
810	Novel Risk Factors for Systemic Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 2481.	7.4	1,117

#	ARTICLE	IF	CITATIONS
811	Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. <i>European Heart Journal</i> , 2001, 22, 2135-2137.	2.2	47
812	Differential Effects of E and Droloxifene on C-Reactive Protein and Other Markers of Inflammation in Healthy Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4216-4222.	3.6	75
813	High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis. <i>European Heart Journal</i> , 2001, 22, 349-352.	2.2	57
814	Mutation in the promoter region of the $\beta_2$ -fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. <i>European Heart Journal</i> , 2001, 22, 2262-2266.	2.2	46
815	Blood Pressure and Inflammation in Apparently Healthy Men. <i>Hypertension</i> , 2001, 38, 399-403.	2.7	594
816	Effect of Statin Therapy on C-Reactive Protein Levels. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 64.	7.4	1,458
817	Statins for Stroke: The Second Story?. <i>Circulation</i> , 2001, 103, 348-350.	1.6	23
818	Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia. <i>Circulation</i> , 2001, 103, 1191-1193.	1.6	405
819	C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 327.	7.4	3,562
820	Soluble P-Selectin and the Risk of Future Cardiovascular Events. <i>Circulation</i> , 2001, 103, 491-495.	1.6	504
821	Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. <i>Vascular Medicine</i> , 2001, 6, 145-149.	1.5	32
822	Genetic Variation in Alcohol Dehydrogenase and the Beneficial Effect of Moderate Alcohol Consumption on Myocardial Infarction. <i>New England Journal of Medicine</i> , 2001, 344, 549-555.	27.0	295
823	Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events. <i>New England Journal of Medicine</i> , 2001, 344, 1959-1965.	27.0	1,512
824	Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. <i>Clinical Chemistry</i> , 2001, 47, 28-30.	3.2	48
825	High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. <i>Clinical Chemistry</i> , 2001, 47, 403-11.	3.2	125
826	Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. <i>Clinical Chemistry</i> , 2001, 47, 426-30.	3.2	125
827	Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. <i>Clinical Chemistry</i> , 2001, 47, 444-50.	3.2	140
828	A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1141-3.	3.4	6

#	ARTICLE	IF	CITATIONS
829	Plasma Concentration of Interleukin-6 and C-reactive Protein and the Risk of Developing Type 2 Diabetes Mellitus Among Healthy Middle-Aged Women. <i>Circulation</i> , 2001, 103, 1351-1351.	1.6	2
830	Relationship of Obesity with C-Reactive Protein and Interleukin-6 in Women. <i>Circulation</i> , 2001, 103, 1348-1348.	1.6	0
831	Plasma Concentration of Cystatin-C and Mannose Binding Protein and the Risk of Developing Peripheral Vascular Disease. <i>Circulation</i> , 2001, 103, 1351-1351.	1.6	3
832	Association of endogenous tissue plasminogen activator (t-PA) with clinical characteristics of the insulin resistance syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 227-231.	2.1	2
833	Blood levels of homocysteine and atherosclerotic vascular disease. <i>Current Atherosclerosis Reports</i> , 2000, 2, 194-199.	4.8	10
834	Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. <i>Current Cardiology Reports</i> , 2000, 2, 269-273.	2.9	15
835	Elevation of Tumor Necrosis Factor- $\alpha$ and Increased Risk of Recurrent Coronary Events After Myocardial Infarction. <i>Circulation</i> , 2000, 101, 2149-2153.	1.6	853
836	Albumin, fibrinogen, von Willebrand factor, factor VIII activity, and leukocyte count are significant nontraditional risk factors for CHD in patients with diabetes. <i>Evidence-based Cardiovascular Medicine</i> , 2000, 4, 89-91.	0.0	0
837	Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men. <i>Circulation</i> , 2000, 101, 1767-1772.	1.6	2,111
838	C-REACTIVE PROTEIN, INFLAMMATION, AND CORONARY RISK. <i>Medical Clinics of North America</i> , 2000, 84, 149-161.	2.5	146
839	Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. <i>Journal of the American College of Cardiology</i> , 2000, 36, 39-43.	2.8	125
840	Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. <i>Journal of the American College of Cardiology</i> , 2000, 36, 423-426.	2.8	151
841	C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. <i>New England Journal of Medicine</i> , 2000, 342, 836-843.	27.0	5,215
842	Novel risk factors and markers for coronary disease. <i>Advances in Internal Medicine</i> , 2000, 45, 391-418.	0.9	46
843	Factor V Leiden Is Not a Risk Factor for Myocardial Infarction Among Young Women. <i>Blood</i> , 1999, 93, 1432-1433.	1.4	12
844	Plasma Concentrations of Interleukin-6 and Abdominal Aortic Diameter Among Subjects Without Aortic Dilatation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1695-1699.	2.4	104
845	Novel Inflammatory Markers of Coronary Risk. <i>Circulation</i> , 1999, 100, 1148-1150.	1.6	369
846	Prospective Study of Chlamydia pneumoniae IgG Seropositivity and Risks of Future Myocardial Infarction. <i>Circulation</i> , 1999, 99, 1161-1164.	1.6	205

#	ARTICLE	IF	CITATIONS
847	Homocysteine and Risk of Cardiovascular Disease Among Postmenopausal Women. JAMA - Journal of the American Medical Association, 1999, 281, 1817.	7.4	221
848	Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein. Circulation, 1999, 100, 230-235.	1.6	1,423
849	Cross-Sectional Study of Soluble Intercellular Adhesion Molecule-1 and Cardiovascular Risk Factors in Apparently Healthy Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1595-1599.	2.4	142
850	The Gene Encoding Atrial Natriuretic Peptide and the Risk of Human Stroke. Circulation, 1999, 100, 1722-1726.	1.6	92
851	Pathogenesis and pathology of coronary heart disease syndromes. , 1999, 8, 167-189.		15
852	Lipid lowering and beyond: Results from the CARE study on lipoproteins and inflammation. Herz, 1999, 24, 51-56.	1.1	20
853	Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis. Current Cardiology Reports, 1999, 1, 88-90.	2.9	4
854	The role of C-reactive protein in cardiovascular disease risk. Current Cardiology Reports, 1999, 1, 99-104.	2.9	62
855	Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. American Journal of Cardiology, 1999, 84, 1018-1022.	1.6	310
856	Assessment of genetic markers for coronary thrombosis: promise and precaution. Lancet, The, 1999, 353, 687-688.	13.7	36
857	High Levels of Plasma C-Reactive Protein and Future Risk of Age-Related Cataract. Annals of Epidemiology, 1999, 9, 166-171.	1.9	81
858	Vasectomy and subsequent cardiovascular disease in US physicians. Contraception, 1999, 59, 181-186.	1.5	21
859	G20210A Mutation in Prothrombin Gene and Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in a Large Cohort of US Men. Circulation, 1999, 99, 999-1004.	1.6	256
860	A prospective study of fibrinogen and risk of myocardial infarction in the physiciansâ€™ health study. Journal of the American College of Cardiology, 1999, 33, 1347-1352.	2.8	134
861	Hormone Replacement Therapy and Increased Plasma Concentration of C-Reactive Protein. Circulation, 1999, 100, 713-716.	1.6	422
862	Prospective Evaluation of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of Stroke. Circulation, 1999, 99, 340-343.	1.6	77
863	Correspondence. American Journal of Medicine, 1999, 106, 267-268.	1.5	29
864	Editorial. American Journal of Medicine, 1999, 106, 376-377.	1.5	12

#	ARTICLE	IF	CITATIONS
865	Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks?. Annals of Internal Medicine, 1999, 130, 933.	3.9	275
866	Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay. Clinical Chemistry, 1999, 45, 2136-2141.	3.2	536
867	Cystatin C deficiency in human atherosclerosis and aortic aneurysms. Journal of Clinical Investigation, 1999, 104, 1191-1197.	8.2	397
868	Factor V Leiden Is Not a Risk Factor for Myocardial Infarction Among Young Women. Blood, 1999, 93, 1432-1433.	1.4	1
869	Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagulation and Fibrinolysis, 1999, 10 Suppl 1, S9-12.	1.0	19
870	Factor V Leiden is not a risk factor for myocardial infarction among young women. Blood, 1999, 93, 1432-3.	1.4	0
871	Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry, 1999, 45, 2136-41.	3.2	175
872	Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet, The, 1998, 351, 88-92.	13.7	1,135
873	Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy Women. Circulation, 1998, 98, 731-733.	1.6	1,491
874	Use and Effectiveness of Intravenous Heparin Therapy for Treatment of Acute Myocardial Infarction in the Elderly 11This study was supported in part by the Patrick and Catherine Weldon Donaghue Medical Research Foundation, Hartford, Connecticut. Dr. Krumholz is a Paul Beeson Faculty Scholar. The analyses on which this publication is based were performed under Contract Number 500-96-P549, titled, "Utilization and Quality Control Peer Review Organization for the State of Connecticut," sponsored by the Health C. Journal of the American College of Cardiology, 1998, 31, 973-979.	2.8	37
875	Circulating Cell Adhesion Molecules Are Correlated With Ultrasound-Based Assessment of Carotid Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1765-1770.	2.4	255
876	C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction. Circulation, 1998, 97, 2007-2011.	1.6	904
877	Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Circulation, 1998, 98, 839-844.	1.6	1,268
878	Inflammation, Infection, and Cardiovascular Risk. Circulation, 1998, 97, 1671-1674.	1.6	134
879	Prospective Study of Herpes Simplex Virus, Cytomegalovirus, and the Risk of Future Myocardial Infarction and Stroke. Circulation, 1998, 98, 2796-2799.	1.6	174
880	Hotline Editorial. European Heart Journal, 1998, 19, 1119-1121.	2.2	28
881	Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. Journal of Investigative Medicine, 1998, 46, 391-5.	1.6	53
882	Elevated plasma homocysteine was associated with increased risk of vascular disease. Evidence-based Cardiovascular Medicine, 1998, 2, 30-2.	0.0	0



#	ARTICLE	IF	CITATIONS
883	Age-Specific Incidence Rates of Venous Thromboembolism among Heterozygous Carriers of Factor V Leiden Mutation. <i>Annals of Internal Medicine</i> , 1997, 126, 528.	3.9	123
884	Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. <i>New England Journal of Medicine</i> , 1997, 336, 973-979.	27.0	5,022
885	PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. <i>Lancet</i> , The, 1997, 349, 385-388.	13.7	361
886	Effects of a Single, Daily Alcoholic Beverage on Lipid and Hemostatic Markers of Cardiovascular Risk. <i>American Journal of Cardiology</i> , 1997, 80, 1226-1228.	1.6	41
887	Fibrinolytic and Inflammatory Markers for Arterial Occlusion: The Evolving Epidemiology of Thrombosis and Hemostasis. <i>Thrombosis and Haemostasis</i> , 1997, 78, 053-059.	3.4	61
888	Prevalence of Factor V Leiden in Accelerated Forms of Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1161-1162.	3.4	3
889	Arterial and Venous Thrombosis Is Not Associated With the 4G/5G Polymorphism in the Promoter of the Plasminogen Activator Inhibitor Gene in a Large Cohort of US Men. <i>Circulation</i> , 1997, 95, 59-62.	1.6	176
890	Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. <i>Circulation</i> , 1997, 95, 2643-2651.	1.6	168
891	Hypertension and Borderline Isolated Systolic Hypertension Increase Risks of Cardiovascular Disease and Mortality in Male Physicians. <i>Circulation</i> , 1997, 95, 1132-1137.	1.6	128
892	Interrelation of Hyperhomocyst(e)inemia, Factor V Leiden, and Risk of Future Venous Thromboembolism. <i>Circulation</i> , 1997, 95, 1777-1782.	1.6	299
893	Effects of Ramipril on Plasma Fibrinolytic Balance in Patients With Acute Anterior Myocardial Infarction. <i>Circulation</i> , 1997, 96, 442-447.	1.6	218
894	Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. <i>JAMA - Journal of the American Medical Association</i> , 1997, 277, 1305-7.	7.4	133
895	Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and hemostasis. <i>Thrombosis and Haemostasis</i> , 1997, 78, 53-9.	3.4	9
896	Postmenopausal hormone replacement therapy and cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 1997, 78, 770-80.	3.4	9
897	Prevalence of factor V Leiden in accelerated forms of coronary artery disease. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1161-2.	3.4	1
898	Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1687-90.	2.4	24
899	Anti-Platelet Effects of 100 mg Alternate Day Oral Aspirin: A Randomized, Double-Blind, Placebo-Controlled Trial of Regular and Enteric Coated Formulations in Men and Women. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1996, 3, 209-212.	2.8	18
900	Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 1996, 334, 1145-1149.	27.0	2,293

#	ARTICLE	IF	CITATIONS
901	Age and Thrombolytic Therapy. <i>Circulation</i> , 1996, 94, 1807-1808.	1.6	7
902	Megatrials for Clinical Decision Making. <i>Annals of Internal Medicine</i> , 1996, 125, 621.	3.9	0
903	Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?. <i>JAMA - Journal of the American Medical Association</i> , 1996, 276, 481-5.	7.4	3
904	Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1996, 3, 209-12.	1.5	9
905	Factor V Leiden and recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 1996, 76, 815-6.	3.4	1
906	Discrimination in absorption or transport of beta-carotene isomers after oral supplementation with either all-trans- or 9-cis-beta-carotene. <i>American Journal of Clinical Nutrition</i> , 1995, 61, 1248-1252.	4.7	159
907	Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors. <i>Journal of Thrombosis and Thrombolysis</i> , 1995, 1, 251-257.	2.1	8
908	Direct comparison of aspirin plus hirudin aspirin plus heparin, and aspirin alone among 12,000 patients with acute myocardial infarction not receiving thrombolysis: Rationale and design of the First American Study of Infarct Survival (ASIS-1). <i>Journal of Thrombosis and Thrombolysis</i> , 1995, 1, 119-124.	2.1	3
909	An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. <i>Trends in Cardiovascular Medicine</i> , 1995, 5, 225-229.	4.9	8
910	Discordance between Meta-analyses and Large-Scale Randomized, Controlled Trials: Examples from the Management of Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 1995, 123, 873.	3.9	112
911	A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. <i>Annals of Epidemiology</i> , 1995, 5, 261-269.	1.9	110
912	Thrombolytic therapy for acute myocardial infarction Applying lessons from randomized trials to community practice. <i>Annals of Epidemiology</i> , 1995, 5, 250-252.	1.9	2
913	Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men. <i>New England Journal of Medicine</i> , 1995, 332, 912-917.	27.0	1,047
914	Supplementation with $\beta^2$ -carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. <i>Atherosclerosis</i> , 1995, 112, 187-195.	0.8	106
915	Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism. <i>Circulation</i> , 1995, 92, 2800-2802.	1.6	208
916	Plasma concentration of lipoprotein(a) and the risk of future stroke. <i>JAMA - Journal of the American Medical Association</i> , 1995, 273, 1269-73.	7.4	33
917	Lipoprotein(a) and Risk of Myocardial Infarction-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1994, 271, 1078.	7.4	0
918	Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.. <i>Circulation</i> , 1994, 90, 2236-2240.	1.6	236

#	ARTICLE	IF	CITATIONS
919	Plasma concentration of endogenous tissue plasminogen activator and the occurrence of future cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , 1994, 1, 35-40.	2.1	22
920	Echocardiographic diagnosis of congenital absence of the pericardium in a patient with VATER association defects. <i>Clinical Cardiology</i> , 1994, 17, 503-504.	1.8	20
921	Prospective study of endogenous tissue plasminogen activator and risk of stroke. <i>Lancet, The</i> , 1994, 343, 940-943.	13.7	313
922	Lipoprotein(a) and risks of cardiovascular disease. <i>Annals of Epidemiology</i> , 1994, 4, 360-362.	1.9	13
923	Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. <i>JAMA - Journal of the American Medical Association</i> , 1994, 272, 929-933.	7.4	203
924	More on the GUSTO Trial. <i>Annals of Internal Medicine</i> , 1994, 121, 818.	3.9	3
925	Endogenous tissue-type plasminogen activator and risk of myocardial infarction. <i>Lancet, The</i> , 1993, 341, 1165-1168.	13.7	600
926	Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. <i>Journal of the American College of Cardiology</i> , 1993, 22, 498-505.	2.8	101
927	Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?. <i>Lancet, The</i> , 1993, 341, 1574-1578.	13.7	54
928	Height and incidence of cardiovascular disease in male physicians.. <i>Circulation</i> , 1993, 88, 1437-1443.	1.6	195
929	Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction. A meta-analysis.. <i>Circulation</i> , 1993, 88, 2575-2581.	1.6	55
930	A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993, 13, 1587-1592.	3.9	15
931	Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.. <i>Circulation</i> , 1993, 87, 1969-1973.	1.6	402
932	Large-Scale Trials of Thrombolytic Therapy for Acute Myocardial Infarction: GISSI-2, ISIS-3, and GUSTO-1. <i>Annals of Internal Medicine</i> , 1993, 119, 530.	3.9	53
933	A prospective study of lipoprotein(a) and the risk of myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 1993, 270, 2195-9.	7.4	69
934	Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.. <i>Circulation</i> , 1992, 85, 1822-1827.	1.6	73
935	An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. <i>Current Opinion in Lipidology</i> , 1992, 3, 285-290.	2.7	26
936	The Primary Prevention of Myocardial Infarction. <i>New England Journal of Medicine</i> , 1992, 326, 1406-1416.	27.0	474

#	ARTICLE	IF	CITATIONS
937	Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction. New England Journal of Medicine, 1992, 327, 7-13.	27.0	209
938	Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction. American Journal of Cardiology, 1992, 70, 10-13.	1.6	130
939	Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. American Heart Journal, 1991, 121, 1835-1838.	2.7	55
940	The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: Clinical evidence from the physicians' health study. American Heart Journal, 1991, 122, 1588-1592.	2.7	57
941	Left ventricular hemangioma in Kasabach-Merritt syndrome. American Heart Journal, 1991, 121, 202-203.	2.7	20
942	Surgical management of carcinoid heart disease. Annals of Thoracic Surgery, 1991, 52, 1208.	1.3	5
943	Aspirin, Platelet Aggregation, and the Circadian Variation of Acute Thrombotic Events. Chronobiology International, 1991, 8, 327-335.	2.0	13
944	Low-Dose Aspirin Therapy for Chronic Stable Angina. Annals of Internal Medicine, 1991, 114, 835.	3.9	181
945	Hemostatic risk factors for coronary heart disease.. Circulation, 1991, 83, 1098-1100.	1.6	36
946	Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy.. Circulation, 1991, 84, 708-711.	1.6	22
947	False Positive Mononucleosis Screening Test Results Associated with Klebsiella Hepatic Abscess. American Journal of Clinical Pathology, 1990, 94, 222-223.	0.7	9
948	Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians.. Circulation, 1990, 82, 897-902.	1.6	278
949	Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. American Journal of Medicine, 1990, 89, 772-776.	1.5	77
950	Streptokinase therapy and cholesterol embolization. American Journal of Medicine, 1989, 87, 357-358.	1.5	33
951	COMFREY HERB TEA AND HEPATIC VENO-OCCLUSIVE DISEASE. Lancet, The, 1989, 333, 657-658.	13.7	93
952	Atrial Fibrillation Induced by Breath Spray. New England Journal of Medicine, 1989, 320, 124-124.	27.0	11
953	Health hazards of unusual herbal teas. American Family Physician, 1989, 39, 153-6.	0.1	8
954	Genetic Testing: Moving to the Bedside—When and How?. , 0, , 47-64.		0